[
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 1
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 2
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 3
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CK1\u03b1",
      "GSPT1",
      "C2H2 ZFs"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 4
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 5
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "Kinases (beyond CK1\u03b1)",
      "RNA-recognition domain",
      "BRK domain",
      "WW domain",
      "Horma domain",
      "HUP domain"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 6
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7",
      "CK1\u03b1",
      "IKZF1",
      "W\u0399\u0396",
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 7
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 9
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 11
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "Kinase 1",
      "Kinase 2",
      "Kinase 3",
      "Kinase 4",
      "Kinase 5",
      "Kinase 6",
      "Kinase 7",
      "Kinase 8",
      "Kinase 9",
      "Kinase 10"
    ],
    "modality": "Promiscuous kinase degrader",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 12
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN:MGD",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 13
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 14
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1",
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "VAV1 identified from cell-based whole proteome screening",
      "VAV1 shows surface similarity to the G-loop degron of GSPT1"
    ],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 15
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1",
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 16
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "potent VAV1-directed MGD",
      "induces selective VAV1 degradation",
      "favorable ADME/DMPK profile"
    ],
    "safety": [
      "IC50 > 30 \u00b5M",
      "EC50 > 30 \u00b5M",
      "> 50%"
    ],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 17
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Novel binding modes broaden target space",
      "Potential benefits for selective MGD design"
    ],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 18
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 19
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": "Cereblon",
    "indications": [
      "Lenalidomide"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 20
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": [
      {
        "name": "CUL3",
        "rank": 1
      },
      {
        "name": "CRBN",
        "rank": 31
      },
      {
        "name": "VHL",
        "rank": 132
      }
    ],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 21
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "MRT-2359 (GSPT1)",
      "MRT-6160 (VAV1)",
      "NEK7",
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "other MYC-driven Malignancies",
      "Autoimmune Disease",
      "Inflammatory Diseases",
      "Ovarian Cancer",
      "Breast Cancer"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Immunology",
      "Inflammation"
    ],
    "clinical_phases": [
      "IND-Enabling",
      "Clinical"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 22
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 23
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "oncology",
      "neurological conditions"
    ],
    "clinical_phases": [
      "Phase I"
    ],
    "claims": [
      "optimal PD modulation",
      "clinical activity",
      "favorable tolerability profile"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 3
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 4
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "oncology",
      "neurological disease"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "$50M upfront payment",
      "potential preclinical, clinical, regulatory and sales milestones that could exceed $2B",
      "potential additional payments including nomination, preclinical, clinical, regulatory and sales milestones"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 5
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": "GSPT1 Program",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase I"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 6
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": "molecular glue degrader (MGD)",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 7
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 is a potent GSPT1 degrader",
      "MRT-2359 induced selective GSPT1 degradation",
      "MRT-2359 showed favorable ADME/DMPK profile"
    ],
    "safety": [
      "CYP DDIs > 30 \u00b5M",
      "hERG inhibition patch clamp EC50 > 30 \u00b5M",
      "Oral bioavailability all species ~50%"
    ],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 8
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "Lung NE"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 9
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359-001",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung cancer (NSCLC & SCLC)",
      "DLBCL",
      "high-grade neuroendocrine tumors",
      "N-/L-MYC amplified solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Demonstrate dose dependent PK",
      "Demonstrate significant GSPT1 degradation at safe dose levels in PBMCs and tissue biopsies (60% based on preclinical data)",
      "Share potential preliminary efficacy signals in biomarker positive patients"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 10
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "non-small cell lung cancer (NSCLC)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "3 dose levels (0.5 mg, 1 mg, 2 mg) have been completed with 21 patients enrolled",
      "Observed dose dependent PK after oral dosing",
      "0.5 mg starting dose was fully active based on pharmacodynamic (PD) assessment",
      "Encouraging initial clinical activity at all dose levels: 2 partial responses (PRs) (1 confirmed, 1 unconfirmed) and 1 stable disease (SD) in 6 evaluable, heavily pretreated patients identified with biomarker positive tumors",
      "1 SD in non-small cell lung cancer (NSCLC) with un-evaluable biomarker status"
    ],
    "safety": [
      "Favorable adverse event (AE) profile at 0.5 and 1 mg",
      "Grade 4 thrombocytopenia identified as dose limiting toxicity (DLT) at 2 mg",
      "No hypotension/cytokine release syndrome or clinically significant hypocalcemia observed at any dose level"
    ],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 11
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Dose dependent exposure in line with preclinical PK",
      "No food effect observed",
      "PD modulation in PBMCs observed across all dose levels; level of degradation (~ 60%) in line with maximal degradation observed in preclinical studies using the same method",
      "Level of degradation equivalent across all dose levels, suggesting saturated PD response from 0.5 to 2 mg"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 12
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": "targeted mass spectrometry",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 reduced GSPT1 expression in human tissue biopsies",
      "GSPT1 degradation assessed from pre-treatment screening biopsies and biopsies taken at day 19",
      "Matched biopsies obtained from 11 patients across the 3 cohorts analyzed",
      "GSPT1 expression assessed using targeted mass spectrometry",
      "PD modulation seen in tissue biopsies in line with PD modulation seen preclinically at efficacious dose levels using same assay (targeted mass spectrometry)"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 13
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "High Grade neuroendocrine bladder cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Confirmed PR in High Grade Neuroendocrine Bladder Cancer",
      "Baseline tumor biopsy demonstrated high N-MYC expression",
      "4 prior lines of therapy including chemotherapy and pembrolizumab",
      "Patient initiated on 2 mg for first 5/9 regimen, then lowered to 1 mg and 0.5 mg and remains on therapy (> 3 month)",
      "CT scan after 4 weeks demonstrated PR (-34% per RECIST 1.1) that continued to improve at week 8 (-59% per RECIST 1.1)"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 15
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC/NE Transformation"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Baseline tumor biopsy demonstrated SCLC/NE transformation, low N- and L-MYC expression",
      "Multiple lines of prior therapy including chemotherapy, pembrolizumab and atezolizumab",
      "CT on C1D22 demonstrated resolution of liver metastases (-41% per RECIST 1.1)"
    ],
    "safety": [
      "Patient experienced frequent dose interruptions due to bowel obstruction unrelated to MRT-2359"
    ],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 16
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "non-small cell lung cancer (NSCLC)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "0.5 mg starting dose was active based on PD assessment",
      "Encouraging initial clinical activity at all dose levels: 2 PRs (1 confirmed, 1 unconfirmed) and 1 SD in 6 evaluable, heavily pretreated patients identified with biomarker positive tumors",
      "1 SD in non-small cell lung cancer (NSCLC) with un-evaluable biomarker status",
      "Favorable AE profile at 0.5 and 1 mg",
      "Grade 4 thrombocytopenia identified as dose limiting toxicity (DLT) at 2 mg",
      "No hypotension/cytokine release syndrome or clinically significant hypocalcemia observed at any dose level"
    ],
    "safety": [
      "Favorable AE profile at 0.5 and 1 mg",
      "Grade 4 thrombocytopenia identified as dose limiting toxicity (DLT) at 2 mg",
      "No hypotension/cytokine release syndrome or clinically significant hypocalcemia observed at any dose level"
    ],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 18
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 19
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": "molecular glue degraders",
    "e3_ligase": null,
    "indications": [
      "MYC-driven cancers",
      "autoimmune diseases"
    ],
    "therapeutic_areas": [
      "oncology",
      "autoimmune",
      "inflammation"
    ],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [
      "potential to treat difficult-to-drug MYC-driven cancers",
      "optimal pharmacodynamic modulation and early signs of clinical activity observed",
      "highly selective VAV1-directed MGD",
      "wide potential applications across autoimmune diseases"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 21
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 22
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 2
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": "Molecular Glue Degraders",
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 3
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "c-MYC",
      "N-MYC",
      "L-MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MYC up-regulation dysregulates key cellular processes (e.g. ribosome biogenesis and protein synthesis)",
      "MYC dysregulation is frequently associated with poor prognosis and unfavorable patient survival",
      "MYCs are considered undruggable by classic methods"
    ],
    "safety": [],
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 4
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": "cereblon",
    "indications": [
      "MYC-driven Solid Tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "GSPT1 MGDs selectively affect MYC-addicted cells",
      "Proteomics reveals selective degradation of GSPT1",
      "Viability effects are cereblon-dependent",
      "MYC expression status governs cell sensitivity to primary hit"
    ],
    "safety": [],
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 5
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": "Oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Optimal selectivity for GSPT1 vs other neosubstrates",
      "Maximal preferential effect (MYC-driven vs non MYC-driven cancers)",
      "Differentiation over other pathway mechanisms/compounds"
    ],
    "safety": [],
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 6
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 achieves a high selective effect (2.4 U) in NSCLC",
      "MRT-2359 has been rationally designed to be in the ADMET sweet-spot",
      "Several compounds with good oral bioavailability discovered (large circles = >40%F po)"
    ],
    "safety": [
      "Compounds with reactive metabolite flag"
    ],
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 7
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 8
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "GSPT2"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Highly Optimized and Potent"
    ],
    "safety": [],
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 9
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "IKZF1",
      "IKZF3",
      "SALL4",
      "ZFP91",
      "CK1a",
      "GAPDH"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Highly Selective",
      "Oral bioavailable",
      "Favorable ADMET profile"
    ],
    "safety": [
      "No activity observed in an in vitro panel of 44 safety targets"
    ],
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 10
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "lung cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Preferential Activity in MYC High Lung Cancer Lines is Unique"
    ],
    "safety": [],
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 15
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "c-MYC",
      "N-MYC",
      "L-MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 leads to rapid and deeper degradation of GSPT1 in cancer cells with high MYC expression",
      "MRT-2359 preferentially impairs protein synthesis in tumor cells with high MYC expression",
      "MRT-2359 indirectly affects MYC expression and transcriptional activity"
    ],
    "safety": [],
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 16
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC N- or L-MYC high",
      "NSCLC N- and L-MYC low",
      "SCLC N- or L-MYC high"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "dose dependent activity",
      "similar efficacy of continuous vs on/off schedule"
    ],
    "safety": [],
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 18
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung cancer (NSCLC & SCLC)",
      "DLBCL",
      "high-grade neuroendocrine tumors",
      "N-/L-MYC amplified solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1: Dose Escalation",
      "Phase 2: Expansion Cohorts"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 19
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": "Molecular Glue Degraders (MGDs)",
    "e3_ligase": "E3 Ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 3
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "QuEEN\u2122 Discovery Platform",
    "targets": [
      "undruggable targets"
    ],
    "modality": "MGDs",
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      ">3000 proteins containing a predicted loop degron"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Genetic disease",
      "Nervous system",
      "Musculoskeletal",
      "Urinary system",
      "Psychiatric disorder",
      "Respiratory system",
      "Neoplasm",
      "Endocrine system",
      "Metabolic disease",
      "Immune system"
    ],
    "therapeutic_areas": [
      "C2H2 zinc finger",
      "Protein kinase",
      "WD40 repeats",
      "Cadherin repeats",
      "RNA recognition motif",
      "EGF-like",
      "Immunoglobulin",
      "Src homology 3",
      "WWP domain",
      "Ring finger"
    ],
    "clinical_phases": [],
    "claims": [
      ">85% degrons have unique sequence",
      ">75% undruggable",
      "Many highly credentialed targets"
    ],
    "safety": [],
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "TK",
      "TKL",
      "STE",
      "CK1",
      "AGC",
      "CMGC",
      "CAMK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Over 170 human kinases have predicted degrons",
      "Degrons occur in kinase, SH3 and other domains",
      "Includes multiple kinases with scaffolding functions",
      "Degrons typically occur outside conserved regions",
      "Sequence homology is more diverse than binding pockets, allowing for more selective engagement"
    ],
    "safety": [],
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "TK",
      "TKL",
      "CMGC",
      "Other",
      "STE",
      "CK1",
      "AGC",
      "CDK2",
      "CAMK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 11
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "metabolic pathologies",
      "cardiovascular diseases",
      "inflammatory issues",
      "neurologic disorders",
      "Cryopyrin-associated periodic syndromes (CAPS)"
    ],
    "therapeutic_areas": [
      "inflammatory disease"
    ],
    "clinical_phases": [],
    "claims": [
      "NEK7 licenses NLRP3 assembly in a kinase independent manner",
      "NEK7-deficient macrophages are severely impaired in IL-1\u03b2 and IL-18 secretion"
    ],
    "safety": [],
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Rationally designed MGDs promote selective CRBN proximity",
      "NEK7-directed MGD promotes selective degradation of NEK7"
    ],
    "safety": [],
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NLRP3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Cryopyrin-associated periodic syndromes",
      "Myocardial infarction",
      "Diabetic cardiomyopathy",
      "Obesity",
      "Type II Diabetes",
      "Artherosclerosis",
      "Parkinson\u2019s disease",
      "Alzheimer\u2019s disease",
      "Multiple sclerosis",
      "ALS",
      "Psychiatric disorders",
      "Inflammatory bowel disease (IBD)",
      "Asthma",
      "ARDS",
      "Liver fibrosis",
      "Liver damage",
      "Nephrotic syndrome",
      "SLE",
      "Gout",
      "Rheumatoid arthritis"
    ],
    "therapeutic_areas": [
      "Heart",
      "Metabolism",
      "Brain",
      "Intestine",
      "Lung",
      "Liver",
      "Kidney",
      "Joints"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 17
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 19
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 3
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": "Molecular Glue Degraders (MGDs)",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Address undruggable space",
      "Orally bioavailable",
      "Systemic distribution",
      "Scalable manufacturing",
      "Reversible"
    ],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": "cereblon",
    "indications": [],
    "therapeutic_areas": [
      "Oncology",
      "Immunology",
      "Neuroscience"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "NEK7 is required for activation of the NLRP3 inflammasome in vivo",
      "Structural licensing of NLRP3 by NEK7 binding"
    ],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "gout",
      "pericarditis",
      "cardiovascular disease",
      "neurodegenerative disease",
      "obesity"
    ],
    "therapeutic_areas": [
      "inflammatory diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "NEK7 licenses NLRP3 assembly in a kinase-independent manner",
      "NEK7-deficient macrophages are severely impaired in IL-1\u03b2 and IL-18 secretion",
      "NEK7 degradation has the potential to become an important treatment modality for a variety of inflammatory diseases"
    ],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "NEK7 MGD \u2013 MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": "MGD",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potent, Selective NEK7-Directed MGD With a Favorable Drug-like Profile",
      "Excellent selectivity profile in different cell lines",
      "Active in human and non-human primates",
      "Not active in rodents",
      "Yes for Oral Bioavailability",
      "No unique human metabolites or GSH adducts (mics)"
    ],
    "safety": [
      "Negative in Mini-Ames",
      "No inhibition (EC50> 30 \u00b5M) in hERG (patch clamp)",
      "No inhibition in Counterscreens (panel with 44 proteins)"
    ],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NLRP3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 15
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-8102 leads to potent inhibition of NLRP3 inflammasome in human and cynomolgus monkey cells in vitro",
      "Reduced IL-1\u03b2 in human and cynomolgus monkey whole blood",
      "Reduced ASC speck formation in human whole blood"
    ],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 16
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-8102 degrades NEK7 in single-dose in vivo studies",
      "MRT-8102 shows deep degradation in U937 xenograft PK/PD model",
      "MRT-8102 shows dose-dependent degradation in cynomolgus monkey"
    ],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 17
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-8102 induces degradation of NEK7 in vivo over several days",
      "In vivo NEK7 degradation leads to inhibition of NLRP3 inflammasome in ex vivo stimulation assay"
    ],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 18
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 19
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8046",
    "targets": [
      "NEK7"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [
      "gout"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Reduces MSU-Driven Effects In Rabbit Gout Model"
    ],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 21
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 22
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "IL-1\u03b2",
      "IL-1\u03b1",
      "NLRP3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Pericarditis"
    ],
    "therapeutic_areas": [
      "Inflammation"
    ],
    "clinical_phases": [],
    "claims": [
      "MRT-8102 inhibits release of both IL-1\u03b2 and IL-1\u03b1 in pyroptosis assay",
      "IL-1\u03b2, downstream of NLRP3 activation, amplifies inflammatory cycle",
      "Colchicine is first line therapy",
      "Rilonacept approved; oral alternatives required"
    ],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 23
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NLRP3",
      "NEK7",
      "IL-1\u03b1",
      "IL-1\u03b2",
      "IL-18",
      "Pro-IL-1\u03b2",
      "Pro-IL-18"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "NEK7 MGD has potential to resolve inflammation by inhibiting pyroptosis",
      "Inhibition of IL-1 driven inflammation",
      "Resolution of inflammation with NEK7 MGD"
    ],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 24
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 25
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 26
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": null,
    "indications": [
      "inflammatory disorders",
      "gout"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "selective",
      "potent",
      "durable NEK7 degrader",
      "inhibition of NLRP3 inflammasome",
      "therapeutic activity in rabbit gout model"
    ],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 28
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 29
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": ">600 ubiquitin E3 ligases",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 2
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 3
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "Cereblon (CRBN)",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CK1a",
      "GSPT1",
      "C2H2 ZF"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "fAIceit-degron\u2122",
    "targets": [
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 11
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7",
      "NEK4",
      "NEK6",
      "NEK9"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 15
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "IKZF1",
      "CK1a",
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 16
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "oncology target"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Novel Degrons"
    ],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 17
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "NEK7",
      "Neosubstrate 3",
      "Neosubstrate 4",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": "E3 Ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 18
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "MGD1",
      "MGD2",
      "MGDN"
    ],
    "modality": null,
    "e3_ligase": "E3 Ligase footprint",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 19
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 20
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 21
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 22
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 2
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 3
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "Predicted kinases"
    ],
    "modality": [
      "TR-FRET (in vitro)",
      "NanoBRET (in cells)"
    ],
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Novel domain types"
    ],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CRBN",
      "CK1\u03b1",
      "mTOR FRB"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CK1\u03b1",
      "mTOR",
      "mTOR FRB"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "IKZF1",
      "W\u0399\u0396",
      "GSPT1",
      "NEK7",
      "CK1\u03b1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Licenses inflammasome assembly",
      "Kinase-independent scaffolding function"
    ],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 11
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7",
      "CK1\u03b1",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 15
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1",
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 16
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1",
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Novel binding mode",
      "G-loop interactions",
      "Backbone-driven",
      "RT-loop interactions",
      "Side chain-driven"
    ],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 18
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "VAV1",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 19
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Target space expansion beyond G-loop degrons",
      "Overcome species-specific CRBN polymorphisms",
      "Improved MGD selectivity profiles"
    ],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 20
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 21
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "MYC",
      "E2F",
      "AR",
      "Cyclin D1",
      "eIF4E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "therapy-resistant mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 + enzalutamide suppress multiple oncogenes including AR*, MYC and Cyclin D1"
    ],
    "safety": [],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 + enzalutamide drove tumor regressions in CDX models of CRPC with various AR alterations including LNCaP and VCaP",
      "MRT-2359 + Pluvicto improved activity over single agents in enzalutamide-resistant, AR-V7 expressing 22Rv1 model"
    ],
    "safety": [],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 11
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Confirmed PR and PSA90 Response in mCRPC with Activating AR Mutation"
    ],
    "safety": [],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 18
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 19
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 20
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MODeFIRe-1",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC with AR mutations"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 21
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 22
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "androgen receptor (AR) mutations"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "metastatic castration resistant prostate cancer (mCRPC)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1/2",
      "Phase 2"
    ],
    "claims": [
      "100% PSA response",
      "Overall disease control rate (DCR) of 64%"
    ],
    "safety": [
      "mild or moderate manageable GI adverse events"
    ],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 23
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 25
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 26
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": null,
    "indications": [
      "MYC-driven Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 1
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "c-MYC",
      "N-MYC",
      "L-MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MYC dependency is observed in many cancer types",
      "MYC dysregulation is frequently associated with poor prognosis and unfavorable patient survival"
    ],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 2
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-driven tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "GSPT1 is a therapeutic vulnerability of MYC-driven tumors which can be targeted using MGD"
    ],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 3
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": "degrader",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      {
        "binding": {
          "CRBN": {
            "Ki": "113 nM"
          }
        }
      },
      {
        "ternary_complex": {
          "EC50": "< 7 nM"
        }
      },
      {
        "degradation": {
          "DC50": "80 nM"
        }
      }
    ],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "IKZF1",
      "IKZF3",
      "SALL4",
      "ZFP91",
      "CK1a",
      "GAPDH"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 is a selective GSPT1-directed MGD",
      "MRT-2359 is orally bioavailable",
      "MRT-2359 has favorable ADMET profile",
      "MRT-2359 does not inhibit or induce major CYPs",
      "MRT-2359 does not inhibit hERG"
    ],
    "safety": [
      "EC50 > 30 \u00b5M",
      "hERG inhibition patch clamp"
    ],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 induces GSPT1 degradation in all cell models",
      "MRT-2359 shows preferential antiproliferative activity in high N-MYC cell lines",
      "N-MYC overexpression sensitizes NCI-H2023 resistant cells to MRT-2359"
    ],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "No differential activity observed with translational initiation inhibitors",
      "No differential activity observed with clinical CDK9 inhibitor",
      "Similar observations with others translation initiation inhibitors"
    ],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 impairs protein synthesis in N-MYC high NSCLC cell lines",
      "MRT-2359 induces ribosome stalling only in N-MYC high cell line",
      "MRT-2359 rapidly and completely abrogates protein synthesis only in N-MYC high cell line"
    ],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "MYC",
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "N-MYC High NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 induces GSPT1 degradation leading to N-MYC protein downregulation in NCI-H1155",
      "Degradation of GSPT1 leads to downregulation of N-MYC transcriptional output in NCI-H1155",
      "Transcriptional modulation of >200 MYC target genes"
    ],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 impairs protein synthesis in high MYC lines",
      "MRT-2359 affects MYC and downstream in high MYC lines"
    ],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC High Lung Cancer",
      "Neuroendocrine Lung Cancer"
    ],
    "therapeutic_areas": [
      "NSCLC",
      "SCLC",
      "NE Lung Cancer"
    ],
    "clinical_phases": [],
    "claims": [
      "Demonstrates Preferential Anti-tumor Activity"
    ],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung cancer (NSCLC & SCLC)",
      "DLBCL",
      "high-grade neuroendocrine tumors",
      "N-/L-MYC amplified solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1: Dose Escalation",
      "Phase 2: Expansion Cohorts"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 15
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [
      "MYC-driven lung cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "first-in-man"
    ],
    "claims": [
      "MRT-2359 is a rationally designed, potent, selective, and orally bioavailable GSPT1-directed MGD",
      "MRT-2359 impairs protein synthesis and affects MYC and its downstream targets in high MYC cell lines",
      "MRT-2359 demonstrates robust anti-tumor activity preferentially in MYC-driven lung cancer models"
    ],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 16
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 17
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 18
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7",
      "NLRP3"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": null,
    "indications": [
      "Gout"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 2
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": "Molecular Glue Degraders (MGDs)",
    "e3_ligase": "cereblon",
    "indications": [],
    "therapeutic_areas": [
      "Oncology",
      "Immunology",
      "Neuroscience"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 4
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": "MGD",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potent, Selective NEK7-Directed MGD With a Favorable Drug-like Profile",
      "Excellent selectivity profile in different cell lines",
      "Active in human and non-human primates",
      "Not active in rodents",
      "Yes for Oral Bioavailability"
    ],
    "safety": [
      "Negative for Mini-Ames",
      "No inhibition (EC50> 30 \u00b5M) for hERG (patch clamp)",
      "No inhibition for Counterscreens (panel with 44 proteins)"
    ],
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 6
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NLRP3 inflammasome"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 7
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7",
      "NLRP3"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": null,
    "indications": [
      "Gout"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 8
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": "MRT-8102",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "In vivo NEK7 degradation leads to inhibition of NLRP3 inflammasome in ex vivo stimulation assay"
    ],
    "safety": [],
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 9
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7",
      "NLRP3"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": null,
    "indications": [
      "Gout"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 10
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 12
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": null,
    "indications": [
      "gout",
      "other inflammatory disorders"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-8102 is a selective, potent and durable NEK7 degrader.",
      "MRT-8102 leads to inhibition of the NLRP3 inflammasome in vitro and in vivo.",
      "MRT-8102 has therapeutic activity in rabbit gout model."
    ],
    "safety": [],
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 13
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 14
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 3
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": "VAV1 Program (MRT-6160)",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 4
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 5
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": "VAV1 MGD MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "Safety",
      "PK and PD Data"
    ],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 7
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "Safety and tolerability"
    ],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 8
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-6160 Displayed a Dose-Dependent Human Pharmacokinetic Profile",
      "MAD ~2-fold increase in exposure at steady state",
      "No food effect"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 9
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Dose-dependent, marked degradation of VAV1 in peripheral blood T cells (> 90%; except DL1)",
      "Similar results observed in peripheral blood B cells",
      "VAV1 protein reduction is sustained, with dose-dependent recovery post treatment"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 11
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Significantly attenuated CD69 upregulation on T and B cells following TCR stimulation, reflecting functional inhibition",
      "Significantly (up to 99%) inhibited IL-2, IFN-\u03b3 and IL-17A secretion from whole blood derived T cells following ex vivo TCR stimulation",
      "Attenuated IL-6 production by 60-90% across dose levels following B-cell stimulation",
      "Pharmacodynamic studies suggest robust functional effects on cytokine production can be achieved with >80% degradation of VAV1"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 12
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Marked suppression of CD69 upregulation (>90%) in peripheral blood T and B cells following TCR stimulation",
      "Similar results observed in peripheral blood B cells following BCR stimulation"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 13
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Significant and sustained suppression of IL-2, IL-17A and IFN-\u03b3 secretion from whole blood following ex vivo stimulation of TCR"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 14
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "description": "MRT-6160 was well tolerated with no serious adverse events (SAE)"
      },
      {
        "description": "Observed treatment-emergent adverse events (TEAE) were mild (82%) or moderate (18%) and self-limiting"
      },
      {
        "description": "Overall TEAE frequency was similar between MRT-6160 and placebo"
      },
      {
        "description": "TEAE observed in 2 or more subjects treated with MRT-6160",
        "details": {
          "SAD": {
            "pain from vessel puncture": 2
          },
          "MAD": {
            "cough": 2,
            "diarrhea": 3,
            "feeling hot": 4,
            "headache": 5,
            "nasal congestion": 2,
            "oropharyngeal pain": 3,
            "pyrexia": 2
          }
        }
      }
    ],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 15
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "immune-mediated diseases"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "significant effects on cytokine production can be achieved following marked and sustained degradation of VAV1",
      "levels of VAV1 degradation consistent with levels of degradation required to induce efficacy in preclinical models",
      "functional impact on cytokine production consistent with levels predicted to be required to achieve efficacy in humans",
      "highly favorable safety profile in humans",
      "clear path into Phase 2 studies and broad potential applications in multiple immune-mediated diseases"
    ],
    "safety": [
      "highly favorable safety profile in humans"
    ],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 16
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": "NEK7 Programs (MRT-8102 and CNS optimized)",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 17
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7",
      "NLRP3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Pericarditis",
      "Gout",
      "Parkinson",
      "Obesity",
      "Atherosclerosis"
    ],
    "therapeutic_areas": [
      "inflammation-driven diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "NEK7 is a Key Regulator of NLRP3 Inflammasomes, IL-1 and IL-18",
      "NEK7 enables NLRP3 assembly in a kinase-independent manner",
      "NEK7-deficient macrophages are severely impaired in IL-1\u03b2 and IL-18 secretion",
      "NEK7 degradation has the potential to become an important treatment for inflammation-driven diseases"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 18
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "recurrent pericarditis",
      "gout",
      "neuroinflammation",
      "epilepsy",
      "atherosclerotic cardiovascular disease",
      "osteoarthritis",
      "weight loss",
      "CAPS"
    ],
    "therapeutic_areas": [
      "cardio-immunology",
      "rheumatology",
      "neurology",
      "autoinflammation"
    ],
    "clinical_phases": [],
    "claims": [
      "Rilonacept (IL-1\u03b1/\u03b2) \u2013 approved for recurrent pericarditis",
      "Canakinumab (IL-1\u03b2) \u2013 approved for gout flares",
      "Belnacasan (CASP1) \u2013 reduction in seizures",
      "Canakinumab (IL-1\u03b2) \u2013 reduction in cardiac events",
      "Canakinumab (IL-1\u03b2) \u2013 decreased rates of knee and hip replacement",
      "Anakinra (IL-1R), canakinumab (IL-1\u03b2), rilonacept (IL-1 \u03b1/\u03b2) \u2013 approved for CAPS"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 20
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Peripheral Inflammatory Diseases",
      "High CRP",
      "Cardio-immunology",
      "Gout",
      "Pseudogout",
      "Osteoarthritis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1 HV",
      "Planned Phase 1 (PoC)"
    ],
    "claims": [
      "Safety, tolerability, and pharmacokinetics in healthy volunteers",
      "NEK7 degradation in blood after single and multiple daily doses",
      "Changes in levels of inflammatory cytokines",
      "Safety, and tolerability of 28-day dosing",
      "Changes in CRP levels in subjects with high CRP",
      "Changes in gout/pseudogout flare pain or osteoarthritic pain",
      "Reduction in frequency of gout/pseudogout flares"
    ],
    "safety": [
      "Safety, tolerability, and pharmacokinetics in healthy volunteers",
      "Safety, and tolerability of 28-day dosing"
    ],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 21
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-8102 potently degrades NEK7",
      "MRT-8102 induces highly selective NEK7 degradation",
      "MRT-8102 exposure results in prolonged PD effect"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 22
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "No MRT-8102 related clinical signs, no changes in immunophenotyping, no gross or clinical pathology findings at any dose level",
      "The NOAEL was the highest dose tested, 150 mg/kg/day (rat) and 100 mg/kg/day (cyno)",
      ">200-fold exposure margin over projected human efficacious dose in both species",
      "No concerns related to in vitro off-targets, mutagenicity, phototoxicity, hERG or in vivo respiratory or CNS safety pharmacology (rat) or CV safety pharmacology (cyno)"
    ],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 23
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 24
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": "CNS-Optimized NEK7 Program",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 25
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Profound NEK7 degradation",
      "Pathway inhibition in vivo"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 26
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 27
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "T cell",
      "B cell",
      "Macrophage"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [
      "Bladder",
      "Brain",
      "Colon",
      "Heart",
      "Kidney",
      "Lymph node",
      "Muscle",
      "Stomach",
      "Tonsil"
    ],
    "clinical_phases": [],
    "claims": [
      "High degradation in immune and blood cells",
      "Catalytic MOA drives sustained PD effect",
      "CRBN is expressed highly in immune cells and immune relevant sites/organs",
      "Exquisite selectivity enables high therapeutic index",
      "Potential to deplete both membrane receptors and intracellular signaling nodes",
      "No MGD induced tox findings in 2 GLP tox studies (VAV1, NEK7)",
      "Degrading upstream nodes modulates multiple cytokines"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 28
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "Neutrophil",
      "Immune complex",
      "NK cell",
      "Monocyte",
      "pDC",
      "Apoptotic cell",
      "mDC",
      "Type I IFN",
      "Complement",
      "Autoantibodies",
      "T cell",
      "B cell"
    ],
    "modality": "Oral IL-1 drugs, \u201cFcRn in a Pill\u201d, \u201cCAR-T in a Pill\u201d",
    "e3_ligase": null,
    "indications": [
      "Asthma & allergies"
    ],
    "therapeutic_areas": [
      "Inflammatory & auto-inflammatory"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 29
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 30
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": "GSPT1 program (MRT-2359)",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 31
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-driven tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "GSPT1 is a therapeutic vulnerability of MYC-driven tumors leading to preferential activity of GSPT1 MGDs"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 32
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "N-MYC",
      "N-MYC High and/or L-MYC High",
      "L-MYC",
      "SCLC L/N-MYC high",
      "Heme",
      "NSCLC N-MYC high SCLC/NE transformation",
      "Neuroendocrine lung cancer",
      "Neuroendocrine tumors",
      "L-/N-MYC amplified tumors",
      "c-MYC High",
      "c-MYC",
      "Prostate cancer AR positive including AR-V7",
      "Breast cancer ER positive metastatic"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 33
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Non-small cell lung cancer",
      "Small cell lung cancer",
      "High-grade neuroendocrine cancer",
      "N-MYC or L-MYC amplified cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 35
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "High-Grade NE Tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 37
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SCLC",
      "NSCLC",
      "high-grade Neuroendocrine Tumors",
      "L-MYC Amplified tumors",
      "N-MYC Amplified tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      {
        "biomarker": "high L-MYC or N-MYC expression",
        "patients": 13,
        "responses": {
          "PR": 1,
          "SD": 4,
          "DCR": "38%"
        }
      },
      {
        "biomarker": "low L-MYC and N-MYC expression",
        "patients": 24,
        "responses": {
          "unconfirmed PR": 1,
          "SD": 3,
          "DCR": "17%"
        }
      }
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 38
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359 and Enzalutamide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Castrate-Resistant Prostate Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "1 PR (confirmed, -57%)",
      "2 SDs",
      "1 PSA response (-90%)"
    ],
    "safety": [
      "Safety profile has been favorable"
    ],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 39
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Refractory CRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Confirmed PR with AR H875Y Mutation"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 40
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CRPC",
      "lung cancer",
      "NE tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "1 PR and 2 SD in first 3 evaluable, heavily pretreated patients with either AR mutations or AR-V7 expression",
      "Opportunity to enroll 20 - 30 patients if positive efficacy signal continues to be observed",
      "Large, high unmet need indication not requiring biomarker-based patient selection",
      "Strategic decision made not to open expansion cohorts in lung cancer and NE tumors",
      "Despite signals of clinical activity, low biomarker positivity in these indications does not support additional studies"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 41
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": "CCNE1 (Cyclin E1) and CDK2 Programs",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 42
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CCNE1",
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Ovarian cancer",
      "Endometrial cancer",
      "ER-positive breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CCNE1 and CDK2 are key drivers of cancers with cyclin dependent kinase pathway alterations",
      "CCNE1 not druggable by conventional modalities",
      "CCNE1 and CDK2 MGDs are expected to achieve greater selectivity versus conventional CDK inhibitors",
      "CCNE1 and CDK2 MGDs are expected to achieve more sustained pathway inhibition compared to inhibitors"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 43
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CCNE1 amplified gastric cancer",
      "CCNE1 amplified breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-50969 inhibits tumor growth in CCNE1 amplified gastric cancer model",
      "MRT-50969 inhibits tumor growth in CCNE1 amplified breast cancer model"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 44
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+ Breast Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-51443 induces robust tumor regression in combination with CDK4/6 inhibition and fulvestrant",
      "MRT-51443 triple combination substantially reduces tumor growth vs. ribo + fulv"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 45
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 46
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 48
    },
    "year": 2025
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 3
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "key regulator and vulnerability of Myc-induced translational addiction"
    ],
    "safety": [],
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MRT-048",
    "targets": [
      "GSPT1"
    ],
    "modality": "Degrader",
    "e3_ligase": null,
    "indications": [
      "Myc-driven Cancers"
    ],
    "therapeutic_areas": [
      "breast cancer"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "p4EBP1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Breast Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MRT-048",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "potent anti-tumor activity",
      "target engagement demonstrated"
    ],
    "safety": [],
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-048 Impairs Protein Translation and Myc Oncogenic Signaling",
      "Myc gene signatures are strongly down-regulated following treatment with MRT-048"
    ],
    "safety": [],
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "Myc"
    ],
    "modality": "MGDs",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": null,
    "indications": [
      "MYC-driven Malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 1
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [
      "MYC-driven tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 3
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": "MGD",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "potent inducer of GSPT1-cereblon proximity",
      "selective GSPT1-directed MGD",
      "oral bioavailability all species"
    ],
    "safety": [
      "CYP DDIs",
      "hERG inhibition patch clamp"
    ],
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 impairs protein synthesis in high MYC lines",
      "MRT-2359 affects MYC and downstream in high MYC lines"
    ],
    "safety": [],
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC high Lung Cancer",
      "Neuroendocrine Lung Cancer"
    ],
    "therapeutic_areas": [
      "NSCLC",
      "SCLC",
      "NE Lung Cancer"
    ],
    "clinical_phases": [],
    "claims": [
      "Demonstrates Preferential Anti-tumor Activity"
    ],
    "safety": [],
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 11
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359-001",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung cancer (NSCLC & SCLC)",
      "DLBCL",
      "high-grade neuroendocrine tumors",
      "N-/L-MYC amplified solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1: Dose Escalation",
      "Phase 2: Expansion Cohorts"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [
      "lung cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "dose escalation phase",
      "first-in-man"
    ],
    "claims": [
      "rationally designed",
      "potent",
      "selective",
      "orally bioavailable",
      "robust antitumor activity especially in MYC-driven lung cancer models"
    ],
    "safety": [],
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "c-MYC",
      "N-MYC",
      "L-MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MYC dysregulation is frequently associated with poor prognosis and unfavorable patient survival",
      "MYC up-regulation dysregulates key cellular processes (e.g. ribosome biogenesis and protein synthesis)",
      "MYC dependency is observed in many cancer types"
    ],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 3
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-driven tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "GSPT1 is a therapeutic vulnerability of MYC-driven tumors which can be targeted using MGD"
    ],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 4
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": "degrader",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 5
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 is a selective GSPT1-directed MGD",
      "MRT-2359 is orally bioavailable",
      "MRT-2359 has favorable ADMET profile",
      "MRT-2359 is neither an inhibitor, nor an inducer of major CYPs",
      "MRT-2359 doesn\u2019t inhibit hERG"
    ],
    "safety": [
      "EC50 > 30 \u00b5M",
      "hERG inhibition patch clamp"
    ],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 6
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 shows preferential activity compared to 'Rapid' GSPT1 degraders",
      "Rapid GSPT1 degraders lack preferential activity in N-MYC high cell lines"
    ],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 9
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Translation Initiation/Elongation Inhibitors Do Not Show Preferential Activity in MYC High NSCLC and SCLC Cell Lines",
      "MRT-2359 shows preferentially activity in MYC high lung lines",
      "Translation initiation and elongation inhibitors lack differential activity"
    ],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 10
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 11
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 impairs protein synthesis in MYC high lines",
      "MRT-2359 affects MYC and downstream in MYC high lines"
    ],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 12
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 15
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 17
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 18
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC High Lung Cancer",
      "Neuroendocrine Lung Cancer"
    ],
    "therapeutic_areas": [
      "NSCLC",
      "SCLC",
      "NE Lung Cancer"
    ],
    "clinical_phases": [],
    "claims": [
      "Demonstrates Preferential Anti-tumor Activity"
    ],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 20
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 21
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 22
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 25
    },
    "year": 2022
  },
  {
    "company": "monte_rosa",
    "program": "GSPT1 degrader",
    "targets": [
      "Myc"
    ],
    "modality": "molecular glue degraders",
    "e3_ligase": null,
    "indications": [
      "Myc-driven cancers"
    ],
    "therapeutic_areas": [
      "oncology",
      "non-oncology"
    ],
    "clinical_phases": [
      "lead program in 2021"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 2
    },
    "year": 2021
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "Molecular Glue Degraders",
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Favorable drug-like properties",
      "Clinically validated",
      "Broad therapeutic application"
    ],
    "safety": [],
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 3
    },
    "year": 2021
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 6
    },
    "year": 2021
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 7
    },
    "year": 2021
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 8
    },
    "year": 2021
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": "cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 10
    },
    "year": 2021
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 11
    },
    "year": 2021
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "NEK7",
      "CDK2",
      "VAV1",
      "BCL11A"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung Cancer (NSCLC, SCLC)",
      "Inflammatory Diseases",
      "Ovarian Cancer",
      "Breast Cancer",
      "T and B Cell Malignancies",
      "Autoimmune Disease",
      "SCD",
      "\u03b2-Thalassemia"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Autoinflammation",
      "Oncology / immunology",
      "Genetic diseases"
    ],
    "clinical_phases": [
      "Discovery",
      "IND-Enabling",
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 12
    },
    "year": 2021
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7",
      "GSPT1",
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "inflammatory disorders",
      "MYC-driven cancers",
      "solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 13
    },
    "year": 2021
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": "cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 14
    },
    "year": 2021
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK1",
      "CDK2",
      "CDK4",
      "CDK9"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CDK2 biochemical hits are selective over CDK1, CDK4 and CDK9",
      "High ATP-binding site conservation",
      "Degron sequences have low homology",
      "MGDs are biochemically selective for CDK2 over other CDK family members",
      "Potential to identify selective MGDs to closely related cyclin-dependent kinases"
    ],
    "safety": [],
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 17
    },
    "year": 2021
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 18
    },
    "year": 2021
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "Cereblon (CRBN)",
    "indications": [],
    "therapeutic_areas": [
      "Oncology",
      "Immunology",
      "Inflammation",
      "Metabolic disorders",
      "Neurodegeneration",
      "Genetic diseases"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 19
    },
    "year": 2021
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NLRP3",
      "IL-1",
      "IL-6",
      "NEK7"
    ],
    "modality": "Neosubstrate-directed MGD",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-8102 induces catalytic NEK7 degradation",
      "MRT-8102 prevents pyroptotic cell death-mediated release of inflammatory cytokines and DAMPs",
      "Mono- and bispecific biologics fail to inhibit pyroptosis"
    ],
    "safety": [],
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase I"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-8102 potently degraded NEK7",
      "MRT-8102 induced highly selective NEK7 degradation",
      "MRT-8102 exposure resulted in prolonged PD effect",
      "DC50 = 2.5 nM",
      "No degradation of other known CRBN neosubstrates",
      "MRT-8102 has potential to avoid on-off pharmacodynamics and off-target toxicities of NLRP3 inhibitors"
    ],
    "safety": [],
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "SAD",
      "MAD",
      "CRP PoC"
    ],
    "claims": [
      "Achieved 80 \u2013 90% NEK7 Degradation in Peripheral Blood T Cells After Single and Multiple Dose Administration"
    ],
    "safety": [],
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Single Dose of MRT-8102 Led to Significant Reduction in Serum hsCRP"
    ],
    "safety": [],
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-8102 induced significant reduction in serum hsCRP during multiple dose administration",
      "Significant proportion of subjects achieved hsCRP reduction to <2 mg/L",
      "61% drop in hsCRP across all subjects regardless of CRP level at baseline",
      "78% of subjects with elevated baseline CRP of >2 mg/L achieved suppression of hsCRP to <2 mg/L",
      "Up to 78% decrease in hsCRP noted in subjects with elevated CRP levels at baseline"
    ],
    "safety": [],
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Obesity",
      "Elevated CRP"
    ],
    "therapeutic_areas": [
      "CVD Risk"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Safety and tolerability of 28 days dosing"
    ],
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 17
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Well tolerated with favorable safety profile with no SAEs",
      "Treatment-emergent AEs were mild to moderate",
      "No evidence of increased infection risk",
      "No dose dependency"
    ],
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 19
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 22
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 25
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 26
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "VAV1 is a Highly Validated Target for Attenuating T- and B-cell Activity",
      "VAV1-/- mice are viable, fertile, and display loss-of-function T- and B-cell phenotypes",
      "Multiple CRISPR screens identified VAV1 as key player in primary human T-cell function",
      "Impaired T-cell proliferation and cytokine production",
      "Impaired B-cell proliferation and immunoglobulin production",
      "Evidence of impaired T-cell dependent B-cell response"
    ],
    "safety": [],
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "high selectivity and potency for human VAV1 in PBMCs",
      "high selectivity and potency for mouse Vav1 in splenocytes"
    ],
    "safety": [],
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-6160 inhibited disease progression and disease severity of a CIA model",
      "MRT-6160 reduced secretion of key disease-associated serum cytokines"
    ],
    "safety": [],
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "VAV1 Degradation by MRT-6160 Exceeds 90% with Significant Functional Inhibition of T and B Cells following a Single Dose Administration",
      "Dose-dependent degradation of VAV1 in peripheral blood T cells",
      "Attenuation of immune cell activation (CD69 expression) and cytokine production in T and B cells"
    ],
    "safety": [],
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "autoimmune/inflammatory disease"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "T cell activation",
      "B cell activation/Plasma cell differentiation",
      "Th17 response",
      "Pro-inflammatory cytokine production"
    ],
    "safety": [],
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 15
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "Cereblon",
      "Neosubstrate"
    ],
    "modality": "Molecular Glue Degraders",
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Clinically validated"
    ],
    "claims": [
      "Favorable drug-like properties",
      "Differentiated target space"
    ],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 2
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": [
      {
        "name": "CRBN",
        "score": 31,
        "ppi_propensity": "Lower"
      },
      {
        "name": "VHL",
        "score": 132,
        "ppi_propensity": "Low"
      },
      {
        "name": "CUL3",
        "score": 1,
        "ppi_propensity": "High"
      }
    ],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 5
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": "Headlong",
    "targets": [
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 6
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 7
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 8
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 10
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 11
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 12
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 13
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 17
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "Target X"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 18
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER positive breast cancer",
      "ovarian cancer",
      "endometrial cancer"
    ],
    "therapeutic_areas": [
      "solid tumors"
    ],
    "clinical_phases": [],
    "claims": [
      "CDK2 is a key driver of cancers with cyclin dependent kinase pathway alterations",
      "MGDs will achieve greater selectivity against other CDKs and kinases in general, as well as more sustained pathway inhibition compared to inhibitors"
    ],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 19
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 20
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK2",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 21
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": [
      {
        "name": "CUL3",
        "score": "#1",
        "PPI_propensity": "high",
        "ligandable_pocket": true
      },
      {
        "name": "CRBN",
        "score": "#31",
        "PPI_propensity": "lower"
      },
      {
        "name": "VHL",
        "score": "#132",
        "PPI_propensity": "low"
      }
    ],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 24
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "E3 ligase Y",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 25
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 26
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 27
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 28
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": [
      "CDK2",
      "Cyclin E1"
    ],
    "targets": [
      "CDK2",
      "Cyclin E1"
    ],
    "modality": "Molecular Glues Degraders",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Novel binding mode (not G-loop engagement) and differentiated MoA over inhibitors",
      "Novel binding mode leveraging a cryptic pocket on cyclin E1"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 3
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": "CDK2 Program",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 5
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER positive breast cancer"
    ],
    "therapeutic_areas": [
      "cancer"
    ],
    "clinical_phases": [],
    "claims": [
      "CDK2 is a key driver of cancers with cyclin dependent kinase pathway alterations",
      "MGDs will achieve greater selectivity against other CDKs and kinases in general",
      "more sustained pathway inhibition compared to inhibitors"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 6
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CDK2 degradation inhibits proliferation",
      "CDK2 degradation arrests CDK2-dependent cells in G1 phase",
      "CDK2 degradation results in reduction of E2F pathway proteins"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 8
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-9643/ribociclib combination delays resistance onset in ER+ model in vitro"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 10
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": "CDK2 Program",
    "targets": [
      "CDK2"
    ],
    "modality": "molecular glue degraders",
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Highly selective CDK2-targeting molecular glue degraders",
      "Best in CDK2-class potential",
      "RB-dependent activity indicates on-target effects and differentiates from clinical-stage CDK2 inhibitors",
      "Efficacy observed in combination with CDK4/6 inhibitors"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 14
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": "Cyclin E1 Program",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 15
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CCNE1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Ovarian cancer",
      "endometrial cancer",
      "gastric cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CCNE1 is a well-recognized human oncogene",
      "Selective degradation of cyclin E1 can target tumors with deregulated cyclin E1"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 16
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "Cyclin E1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-50969 is a Potent and Highly Selective Cyclin E1-directed MGD",
      "Cyclin E1 degradation leads to downstream pathway suppression",
      "MRT-50969 is highly selective for cyclin E1",
      "MRT-50969 induces robust G1/S cell cycle arrest"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 18
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "E2F targets",
      "Non-E2F",
      "Cyclin E1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 19
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Cyclin E1 MGD-Induced Growth Suppression and Senescence Induction is Mediated by RB",
      "Loss of RB blunts growth suppression induced by MRT-50969",
      "Induction of senescence by cyclin E1 degradation is RB-dependent"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 20
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 21
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 24
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "cyclin E1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "gastric cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-50969 inhibits tumor growth in CCNE1 amplified gastric cancer model",
      "MRT-50969 degrades cyclin E1 and inhibits downstream pathway activity in vivo"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 26
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": "Cyclin E1 Program",
    "targets": [
      "cyclin E1"
    ],
    "modality": "molecular glue degraders",
    "e3_ligase": null,
    "indications": [
      "ovarian",
      "endometrial",
      "gastric",
      "breast"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "First-in-class, highly selective cyclin E1-targeting molecular glue degraders",
      "Sensitivity to cyclin E1 MGD parallels genetic dependency",
      "CCNE1 amplified cell lines are sensitive to cyclin E1 degradation",
      "RB-dependent activity indicates on-target effects",
      "Monotherapy efficacy seen in CCNE1-amplified cancer models in vivo"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 27
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 28
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 29
    },
    "year": 2024
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "Molecular Glue Degraders",
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "powerful and differentiated approach to eradicate disease-causing proteins",
      "clinically validated",
      "broad therapeutic application"
    ],
    "safety": [
      "favorable drug-like properties"
    ],
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 3
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      ">3000 predicted degron-containing proteins",
      ">75% undruggable",
      ">85% degrons have unique sequence"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Genetic disease",
      "Nervous system",
      "Musculoskeletal",
      "Urinary system",
      "Psychiatric disorder",
      "Respiratory system",
      "Neoplasm",
      "Endocrine system",
      "Metabolic disease",
      "Immune system"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "Kinase",
      "Demethylase",
      "Phosphatase",
      "DNA binding",
      "GEF",
      "RNA binding",
      "WD repeat"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Immunology/ Inflammation",
      "Cancer",
      "I-O",
      "Neurology",
      "Genetic Diseases",
      "Solid tumors",
      "T-cell exhaustion",
      "ALS",
      "Blood",
      "T-cell development",
      "Hematological cancers",
      "Tregs",
      "Spastic Paraplegia"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "G-loop",
      "X-loop"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": "chemoproteomics",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Turbo-ID data for 15 representative MGDs",
      "Unbiased discovery of novel and known degron containing proteins",
      "Chemoproteomics enables rapid target deconvolution and identification of novel degron containing targets"
    ],
    "safety": [],
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 11
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "Transcription Factor A",
      "Transcription Factor B"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [
      "sickle cell disease",
      "hematologic malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 15
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK1",
      "CDK2",
      "CDK4",
      "CDK9"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MGDs are biochemically selective over CDK1, CDK4 and CDK9",
      "MGDs promote CDK2-cereblon proximity and are selective over other CDKs",
      "CDK2 EC50 = 61 nM"
    ],
    "safety": [],
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 17
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Rationally designed MGDs promote more selective CRBN proximity",
      "Rationally designed MGDs selectively degrade CDK2"
    ],
    "safety": [],
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 18
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MGD programs",
    "targets": [
      "GSPT1",
      "NEK7",
      "CDK2",
      "VAV1",
      "BCL11A"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung Cancer (NSCLC, SCLC)",
      "Inflammatory Diseases",
      "Ovarian Cancer",
      "Breast Cancer",
      "T and B Cell Malignancies",
      "Autoimmune Disease",
      "SCD",
      "\u03b2-Thalassemia",
      "Multiple",
      "Oncology",
      "Autoinflammation",
      "Oncology / immunology",
      "Genetic diseases"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Discovery",
      "IND-Enabling"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 19
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Oncology",
      "Immunology",
      "Neuroscience",
      "other therapeutic areas"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 3
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "Target 1",
      "Target 2",
      "Target 3",
      "Target 4",
      "Target N"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [
      "oncology",
      "immunology/inflammation"
    ],
    "clinical_phases": [],
    "claims": [
      "Unique Target Space",
      "Unprecedented Selectivity",
      "Catalytic Mechanism of Action",
      "Disease-agnostic platform with initial focus on highly credentialed, undruggable oncology and immunology/inflammation targets",
      "Unique insights into anatomy of protein-protein-MGD interaction allows unprecedented MGD selectivity",
      "Long lasting, catalytic protein degradation effect creates differentiated target product profiles"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "GSPT1/MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-driven tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "GSPT1 is a therapeutic vulnerability of MYC-driven tumors leading to preferential activity of GSPT1 MGDs"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": "MGD",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 is a potent GSPT1-directed MGD",
      "MRT-2359 induces selective GSPT1 degradation",
      "MRT-2359 shows favorable ADME/DMPK profile",
      "No degradation of other known cereblon neosubstrates"
    ],
    "safety": [
      {
        "CYP DDIs": "> 30 \u00b5M"
      },
      {
        "hERG inhibition patch clamp": "EC50 > 30 \u00b5M"
      },
      {
        "Oral bioavailability all species": "~50%"
      }
    ],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 has optimized depth of degradation to achieve preferential activity in MYC high cancer cells",
      "MRT-2359 displays preferential activity in MYC driven NSCLC cells",
      "Non-optimal GSPT1 MGD (MRT-2136) shows limited preferential activity"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung Cancer"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 11
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AR positive prostate cancer"
    ],
    "therapeutic_areas": [
      "prostate cancer"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359-001",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung cancer",
      "high-grade neuroendocrine tumors",
      "solid tumors with N-/L-MYC amplification",
      "HR+/Her2- Breast cancer (+Fulv)",
      "Prostate cancer (+Enza)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 reduced GSPT1 protein expression in human tissue biopsies",
      "GSPT1 degradation assessed from pre-treatment screening biopsies and biopsies taken at day 19",
      "Matched biopsies obtained from 11 patients across the 3 cohorts analyzed",
      "GSPT1 expression assessed using targeted mass spectrometry",
      "PD modulation seen in tissue biopsies in line with PD modulation seen preclinically at efficacious dose levels using same assay (targeted mass spectrometry)"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 15
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": "VAV1/MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 17
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "inflammatory bowel disease",
      "rheumatoid arthritis",
      "multiple sclerosis",
      "myasthenia gravis"
    ],
    "therapeutic_areas": [
      "autoimmune diseases",
      "inflammatory disorders"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 18
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potentially broadly responsive to VAV1 MGD",
      "deep modulation of multiple cytokine pathways with a first-in-class VAV1 oral MGD may benefit patients presenting a broad range of pathophysiology"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 19
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": "MGD",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-6160 is a potent VAV1-directed MGD",
      "MRT-6160 induces highly selective VAV1 degradation",
      "MRT-6160 has a favorable ADME/DMPK profile",
      "No degradation of other known cereblon neosubstrates"
    ],
    "safety": [
      {
        "CYP DDIs": "IC50 > 30 \u00b5M"
      },
      {
        "hERG inhibition patch clamp": "EC50 > 30 \u00b5M"
      },
      {
        "Oral bioavailability all species": "> 50%"
      }
    ],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 20
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 22
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Ulcerative Colitis"
    ],
    "therapeutic_areas": [
      "Inflammation"
    ],
    "clinical_phases": [],
    "claims": [
      "MRT-6160 reduces inflammation-mediated damage and swelling of the colon",
      "MRT-6160 reduces cytokine production in the mesenteric lymph node and colon"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 23
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1 SAD/MAD"
    ],
    "claims": [
      "Provide early insights into safety, PK/PD, and effects on key immunomodulatory signaling pathways"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 24
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "autoimmune/inflammatory disease"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "T cell activation",
      "B cell activation/Plasma cell differentiation",
      "Th17 response",
      "Pro-inflammatory cytokine production"
    ],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 25
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 26
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 27
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 28
    },
    "year": null
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 2
    },
    "year": 2023
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": null,
    "indications": [
      "MYC-driven tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MYC-driven tumors are addicted to protein translation",
      "GSPT1 is a therapeutic vulnerability of MYC-driven tumors"
    ],
    "safety": [],
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 3
    },
    "year": 2023
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 2
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": "novel modalities",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": "Targeted Protein Degradation",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "undrugged targets"
    ],
    "modality": "new modality",
    "e3_ligase": "novel E3s",
    "indications": [
      "oncology",
      "immunology"
    ],
    "therapeutic_areas": [
      "I&I"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "biological and clinical superiority of degrader vs. SMIs"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 11
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Immunology",
      "Oncology",
      "Infectious Disease",
      "CNS",
      "Cardio-Metabolic",
      "Other"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Oral Degraders Can Offer Biologic-like Efficacy in a Pill",
      "Degraders can provide comparable pathway inhibition to biologics, convenience of oral dosing, ease of manufacturing and potentially access broader populations"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4"
    ],
    "modality": "Oral Degraders",
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD",
      "RA",
      "Asthma",
      "COPD",
      "IBD"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Best-in-pathway profile opportunity",
      "Superiority in Phase 1/2"
    ],
    "safety": [
      "IRAK4 null adults: healthy"
    ],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": "oral small molecule",
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma",
      "COPD",
      "CRSwNP",
      "EoE",
      "PN",
      "others"
    ],
    "therapeutic_areas": [
      "Allergic Th2 Inflammation"
    ],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [
      "Dupilumab-like activity"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 18
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 19
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "TYK2"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "IBD",
      "PsO",
      "PsA",
      "Lupus"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Best-in-pathway profile opportunity",
      "TYK2 degrader recapitulates LOF phenotype: biologic-like activity and convenience of oral pill"
    ],
    "safety": [
      "LOF variant is protective in immunological diseases and generally normal"
    ],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 20
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 21
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": [
      "IRAK4",
      "STAT6",
      "TYK2"
    ],
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Clinical opportunities",
      "Degrader advantage",
      "Compelling preclinical data package",
      "Timelines to clinic"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 24
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": "IRAK4",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 26
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "RA",
      "CAPS",
      "HS",
      "AD",
      "Gout",
      "Macrophage Activation Syndrome",
      "Generalized Pustular Psoriasis",
      "Asthma"
    ],
    "therapeutic_areas": [
      "immune-inflammatory diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "IRAK4 degradation is the only approach to fully block the pathway",
      "IRAK4 degradation has the potential to achieve a broad, well-tolerated anti-inflammatory effect"
    ],
    "safety": [
      "Adult humans with IRAK4 null mutation are healthy"
    ],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 27
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Asthma",
      "CD",
      "COPD",
      "RA",
      "HS",
      "UC",
      "SLE"
    ],
    "therapeutic_areas": [
      "DERMATOLOGY",
      "RESPIRATORY",
      "GI",
      "RHEUMATOLOGY"
    ],
    "clinical_phases": [],
    "claims": [
      "Total Potential Patient Impact1: >150M patients",
      "Numerous indication opportunities across multiple therapeutic areas validated by sub-optimal pathway inhibitors",
      "IRAK4 degradation leading to full pathway inhibition has the potential to deliver superior profile to upstream biologics",
      "Oral degrader medicines offer opportunity to reach broader patient populations"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 28
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4"
    ],
    "modality": "Degrader",
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD"
    ],
    "therapeutic_areas": [
      "inflammation"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "Only Degrader Can Fully Block Inflammation",
      "IRAK4 degradation reduces signs and symptoms of HS and AD, while IRAK4 SMI inactive in Phase 2 HS trial",
      "IRAK4 blocks inflammation in blood and skin of HS and AD patients"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 29
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "TNF-a",
      "IL-17",
      "JAK/STAT",
      "IL-4/IL-13",
      "OX40/OX40-L"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Hidradenitis Suppurativa",
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [
      "Chronic inflammatory skin disease"
    ],
    "clinical_phases": [],
    "claims": [
      "Potential for broad anti-inflammatory effect",
      "Competitive efficacy vs. pathway biologics",
      "Convenience of once-daily oral dosing"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 31
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Compelling Data",
      "Early POC"
    ],
    "safety": [
      "Generally well-tolerated across all dose groups",
      "Safety, PK and PD comparable to healthy volunteers"
    ],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 32
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "High fidelity of PKPD translation from preclinical species to humans.",
      "Human efficacious concentrations (Ctrough 3 ng/mL) and doses (50-200 mg) were correctly predicted"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 33
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "High Skin Exposure and Degradation in Skin of HS and AD Patients",
      "High KT-474 Exposure in HS and AD Patients Skin",
      "Reduced IRAK4 in Skin Lesions of AD and HS Patients"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 34
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Moderate to Severe HS"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "HiSCR50 response rate of up to 50%",
      "pain reduction of up to 66%"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 35
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": "oral degrader",
    "e3_ligase": null,
    "indications": [
      "inflammatory diseases",
      "HS",
      "AD"
    ],
    "therapeutic_areas": [
      "anti-inflammatory"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Robust IRAK4 degradation",
      "Favorable safety profile",
      "Systemic suppression of proinflammatory cytokines and chemokines",
      "Early signs of strong clinical activity"
    ],
    "safety": [
      "Favorable safety profile"
    ],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 38
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": "Oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Dupilumab-like activity"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 39
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 40
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic dermatitis",
      "Asthma",
      "CRSwNP",
      "Eosinophilic Esophagitis",
      "Prurigo Nodularis",
      "COPD"
    ],
    "therapeutic_areas": [
      "allergic diseases"
    ],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 41
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": "Oral degrader medicines",
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Asthma",
      "PN",
      "COPD",
      "CRSwNP",
      "EoE"
    ],
    "therapeutic_areas": [
      "DERMATOLOGY",
      "RESPIRATORY",
      "ENT",
      "GI"
    ],
    "clinical_phases": [],
    "claims": [
      "Total Potential Patient Impact: >150M patients",
      "STAT6 degradation leading to full pathway inhibition has the potential to deliver dupilumab-like activity",
      "Numerous indication opportunities across multiple therapeutic areas de-risked by dupilumab"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 42
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": "Degrader",
    "e3_ligase": null,
    "indications": [
      "Allergic Th2 Inflammation"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "STAT6 is the specific and essential transcription factor in the IL-4/13 pathway",
      "Only degradation of STAT6 can block its activity fully and match dupilumab pathway blockade in vitro and in vivo"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 43
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 44
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Complete STAT6 degradation selectivity in human PBMC proteome at 100 x DC90",
      "No other STATs are degraded to any extent"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 45
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 46
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-621 Achieves Dose Dependent Deep Degradation of STAT6 in vivo with Low Oral Doses",
      "KT-621 potently degrades STAT6 across multiple preclinical species",
      "KT-621 can degrade STAT6 to depletion with low oral doses"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 48
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": "oral dosing",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "disease relevant tissues"
    ],
    "clinical_phases": [],
    "claims": [
      "Deep degradation of STAT6 in NHP after 14 days of daily oral dosing"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 49
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "atopic dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-621 has comparable in vivo efficacy to IL-4R\u03b1 saturating dose of Dupilumab in the MC903 atopic dermatitis model"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 50
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-621 has comparable or superior in vivo efficacy to IL-4R\u03b1 saturating dose of Dupilumab in the intranasal HDM asthma model."
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 51
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": "oral small molecule",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "atopic dermatitis",
      "lung inflammation"
    ],
    "clinical_phases": [
      "FIH: 2H 2024"
    ],
    "claims": [
      "Dupilumab-like efficacy",
      "Full IL-4 and IL-13 functional inhibition with picomolar IC50s superior to dupilumab",
      "Robust efficacy shown in in vivo models equal or superior to dupilumab"
    ],
    "safety": [
      "Well-tolerated in multiple preclinical safety studies at >40x efficacious concentration"
    ],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 52
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": "KT-294",
    "targets": [
      "TYK2"
    ],
    "modality": "Oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 53
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 54
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Plaque Psoriasis",
      "CD",
      "PsA",
      "MS",
      "UC",
      "SLE"
    ],
    "therapeutic_areas": [
      "Dermatology",
      "Gastroenterology",
      "Rheumatology",
      "CNS"
    ],
    "clinical_phases": [],
    "claims": [
      "Total Potential Patient Impact: > 20M patients",
      "Numerous indication opportunities across multiple therapeutic areas de-risked by biologics and deucravacitinib",
      "TYK2 degradation, differentiated from inhibition, leads to full pathway inhibition with potential to deliver biologic-like activity",
      "Oral degrader medicines offer opportunity to reach broader patient populations"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 56
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "TYK2 complete deficiency severely impairs IL-23, Type I IFN, and IL-12 signaling but spares IL-10 in humans",
      "TYK2 scaffolding functions are demonstrated by differential pathway inhibitions in complete TYK2 deficiency vs a kinase dead variant in humans",
      "TYK2 deficient humans are generally healthy with only increased risk of some mycobacteria and viral infections that are relatively mild, curable and tend not to recur, de-risking safety for TYK2 degradation",
      "Degrading TYK2 is the only small molecule approach to eliminate all scaffolding and catalytic functions of TYK2, fully recapitulating the human TYK2-/- biology"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 58
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "TYK2"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Highly Selective Picomolar TYK2 Degrader",
      "Fully Inhibits Type I IFN and IL-12/23",
      "Spares IL-10/22"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 59
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-294, Unlike Allosteric TYK2 Inhibitor Deucravacitinib, Does not Inhibit IL-10",
      "IL-10 has essential roles in intestinal homeostasis",
      "Loss of function mutations of the IL-10 pathway cause early onset refractory colitis in humans",
      "Deucravacitinib inhibits IL-10 through JAK1",
      "Deucra JAK1 Ki = 0.33 nM (Burke et al. Sci Transl Med. 2019)",
      "KT-294 JAK1 Ki = > 1000 nM",
      "Deucra Inhibited IL-10 induced pSTAT3 in TYK2 KO EBV B Cell",
      "Deucra Inhibited IL-10 Induced pSTAT3 in Human CD14 Monocyte",
      "Deucra Inhibits IL-10\u2019s Function of Suppressing LPS Induced TNF-\u03b1 Release in Human CD14 Monocyte",
      "KT-294 IC50 = > 1000 nM",
      "Deucravacitinib IC50 = 64 nM",
      "KT-294 IC50 = > 1000 nM",
      "Deucravacitinib IC50 = 89 nM"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 60
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "SG15",
      "IFI6",
      "IFI27",
      "SPATS2L",
      "LY6E",
      "IFI44L",
      "OAS3",
      "OAS1",
      "USP18",
      "SIGLEC1",
      "IFIT1",
      "IFI44",
      "HERC5",
      "RTP4",
      "OAS2",
      "MX1",
      "EPSTI1",
      "RSAD2",
      "IFIT3",
      "LAMP3",
      "PLSCR1",
      "DEFB1",
      "ISG15",
      "DSP",
      "HPSE",
      "ZBP1",
      "HMOX1",
      "HSPA1A",
      "BST2",
      "CYSTM1",
      "DHX58",
      "PSMD9",
      "ARL8A"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 61
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "TYK2"
    ],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Dose Dependent Deep Degradation of TYK2 in vivo with Low Oral Doses",
      "KT-294 potently degrades TYK2 across multiple preclinical species",
      "In NHP, KT-294 can degrade TYK2 to depletion with low oral doses"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 62
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "TYK2",
      "IL-23 p19"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Psoriasis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "TYK2 SMI\u2019s Do Not Reach Maximal Target Engagement",
      "Clinical Efficacy In Psoriasis is Target Engagement Dependent"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 63
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": "KT-294",
    "targets": [
      "TYK2"
    ],
    "modality": "oral degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "FIH: 1H 2025"
    ],
    "claims": [
      "Potential Best-in-Class Opportunity with Biologic-like Profile",
      "Degrades TYK2 in human cells with pM potency",
      "Recapitulates the phenotype of TYK2 human deficiency showing potent IFN-\u03b1, IL-12 and IL-23 inhibition and sparing IL-10",
      "Dosed orally, shows complete TYK2 degradation in NHP providing a path to full target engagement in clinic, unlike current SMI"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 65
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "genetically validated targets/pathways"
    ],
    "modality": "oral small molecules",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "I&I"
    ],
    "clinical_phases": [],
    "claims": [
      "best-in-industry oral I&I pipeline",
      "first-in-class",
      "highly valuable programs"
    ],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 67
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4",
      "STAT6",
      "TYK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "SLE",
      "AD",
      "Asthma",
      "COPD",
      "PsO",
      "IBD",
      "MS",
      "RA"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 69
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4",
      "STAT6",
      "TYK2",
      "STAT3",
      "MDM2"
    ],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 2",
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera R.pdf",
      "slide": 72
    },
    "year": null
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 1
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6 (KT-621)",
      "IRF5 (KT-579)"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 2
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 4
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 8
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Kymera has delivered >9 development candidates, including 4 transcription factors in past 5 years",
      "Highly potent degraders (sub-nanomolar) with refined drug-like properties (orally bioavailable with systemic distribution to all target tissues)",
      "Comprehensive understanding of PK/PD, resulting in impeccable translation of our pipeline into the clinic across programs"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 10
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "S T A T 6",
      "I R F 5",
      "I R A K 4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 11
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6",
      "IRF5",
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Allergic TH2 Inflammation",
      "Th1/Th2/Th17 Inflammation"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "STAT6 is the only specific transcription factor responsible for IL-4/IL-13 signaling",
      "IRF5 is a genetically validated transcription factor and a master regulator of immunity",
      "IRAK4 is master regulator of innate immunity with scaffolding and kinase functions"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 12
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6 KT-621",
      "IRF5 KT-579",
      "IRAK4 KT-4741"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "HS",
      "CSU",
      "PN",
      "BP",
      "Asthma",
      "COPD",
      "CRSwNP",
      "IBD",
      "EoE",
      "RA",
      "SLE",
      "SSc",
      "j\u00f6gren\u2019s",
      "DM"
    ],
    "therapeutic_areas": [
      "Dermatology",
      "Respiratory",
      "GI",
      "Rheumatology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 13
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6",
      "IRF5",
      "IRAK4"
    ],
    "modality": "Oral Small Molecule Degraders",
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma",
      "COPD",
      "PN",
      "CRSwNP",
      "EoE",
      "BP",
      "CSU",
      "Lupus",
      "Sj\u00f6gren's",
      "RA",
      "IBD",
      "SSc",
      "DM"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b",
      "Phase 2b"
    ],
    "claims": [
      "Biomarkers in blood & skin lesions",
      "28-day efficacy",
      "Safety",
      "degradation"
    ],
    "safety": [
      "Partnered with Sanofi/Kymera Opt-In Potential"
    ],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 15
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": "STAT6 (KT-621)",
    "targets": [],
    "modality": "Dupilumab-like Activity in a Pill",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 16
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "CSU",
      "PN",
      "BP",
      "EoE",
      "Asthma",
      "COPD",
      "CRSwNP"
    ],
    "therapeutic_areas": [
      "DERMATOLOGY",
      "RESPIRATORY",
      "GASTROENTEROLOGY"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 18
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": "KT-6",
    "targets": [
      "STAT6"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Excellent Degradation Potency and Selectivity",
      "Complete STAT6 Degradation Selectivity in Human PBMC Proteosome at 100 x DC90",
      "Picomolar Potency and Consistent Degradation Across all Disease-Relevant Cell Types Evaluated"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 19
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-621 Degrades STAT6 at Low Oral Doses in All Relevant Tissues",
      "Dose Responsive STAT6 Degradation in Dog Blood Post 7 Days of KT-621 QD Oral Dosing",
      "STAT6 Degradation in All Relevant Tissues in NHP Post 14 Days of KT-621 (10 mpk QD) Oral Dosing"
    ],
    "safety": [
      "No adverse safety findings in any doses of 4-week GLP tox studies in NHP and rodents"
    ],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 21
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [
      "Demonstrate that KT-621 has a dupilumab-like biomarker signature in blood and skin lesions"
    ],
    "safety": [
      "14-day safety follow-up"
    ],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 24
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": "IRF5 (KT-579)",
    "targets": [
      "IRF5"
    ],
    "modality": "Oral Degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 26
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 27
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IRF5"
    ],
    "modality": "oral degrader",
    "e3_ligase": null,
    "indications": [
      "Lupus",
      "RA"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "potent",
      "selective",
      "broad potential utility",
      "robust activity",
      "well-tolerated"
    ],
    "safety": [
      "well-tolerated in safety studies up to 200-fold above the predicted human efficacious concentration"
    ],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 28
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE",
      "RA",
      "IBD",
      "SSc",
      "MS"
    ],
    "therapeutic_areas": [
      "autoimmune diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "IRF5 Genetically Validated in Multiple Autoimmune Diseases",
      "KO mice are viable and fertile; with normal B cell development",
      "IRF5 risk haplotypes and hyperactivated IRF5 levels in SLE patients associated with high serum IFN\u03b1 levels, anti-dsDNA or anti-RNA binding protein antibodies",
      "Genetic associations and functional variants also identified in RA, IBD, SSc, and MS",
      "IRF5 KO mouse can protect or attenuate disease in models of SLE, SSc, RA and IBD",
      "In a mouse model of lupus (FcyIIB-/-, Yaa) IRF5 plays an essential role in lupus pathogenesis, that is independent of Type I IFN pathways",
      "Meta-analyses Identified IRF5 as a Risk Locus for SLE",
      "IRF5 KO Increases Survival and has Essential Role in Lupus",
      "Type I IFN Modestly Protects Against Lupus"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 31
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE",
      "Sj\u00f6gren\u2019s",
      "RA",
      "IBD"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "IRF5 degradation has the potential to selectively block inflammation and restore immune regulation by inhibiting pro-inflammatory cytokines, Type I IFN and autoantibody production",
      "Blocking IRF5 activity has the potential for more effective, tolerated and durable responses in autoimmune diseases"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 32
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE",
      "RA"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Degradation and selectivity",
      "Inhibition of pro-inflammatory cytokines",
      "Type-I IFN inhibition",
      "Autoantibodies inhibition"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 34
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "pro-inflammatory cytokines",
      "Type-I IFN",
      "Autoantibodies"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE",
      "RA"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Degradation and selectivity",
      "Inhibition of pro-inflammatory cytokines",
      "Type-I IFN inhibition"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 35
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRF5"
    ],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 36
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-579 selectively depletes IRF5 downstream of TLR activation",
      "KT-579 degrades all cytoplasmic and nuclear IRF5 (but not IRF3/7)",
      "IRF5 degradation in human monocytes selectively depletes TLR7/8 induced IRF5 nuclear translocation, while sparing IRF7 and IRF3"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 37
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "pro-inflammatory cytokines",
      "Type-I IFN",
      "Autoantibodies"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE",
      "RA"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Degradation and selectivity",
      "Inhibition of pro-inflammatory cytokines",
      "Type-I IFN inhibition"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 40
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "TNF\u03b1",
      "IL-12p40",
      "IL-6",
      "IL-1\u03b2",
      "IFN\u03b2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE"
    ],
    "therapeutic_areas": [
      "autoimmune diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "KT-579 Effectively Blocks Pro-inflammatory Cytokines and Type I IFN Induction in SLE Patient Samples",
      "KT-579 inhibits pro-inflammatory cytokines and Type I IFN that are commonly elevated in autoimmune diseases"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 41
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-579 Significantly Inhibits IgG Levels in Human SLE Patient Samples",
      "KT-579 Inhibits IgG Levels After TLR9 Activation (CpG-B)",
      "KT-579 reduces TLR9 (CpG-B) induced plasmablast differentiation and inhibits IgG production in SLE derived B cells"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 42
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE",
      "RA"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Degradation and selectivity",
      "Inhibition of pro-inflammatory cytokines",
      "Type-I IFN inhibition",
      "Autoantibodies inhibition"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 43
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "TLR7",
      "TLR9"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-579 Effectively Blocks Circulating Cytokines In Mouse Model",
      "KT-579 Leads to Significant Dose-dependent Inhibition of TLR7-R848 and TLR9-CpG-B Cytokine Production in Mouse",
      "KT-579, not M5049 (TLR7/8 SMI), blocks both TLR7 and TLR9 induced cytokines, including TNF\u03b1, IL-6, IL-12p40, IFN\u03b2"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 44
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "IRF5 Degradation Demonstrated Generally Better Outcomes than Approved or Clinically Active Drugs in NZBW1 Spontaneous1 Mouse Lupus Model",
      "Decreased Proteinuria",
      "Early, Sustained and Complete Reduction in Anti-dsDNA Abs",
      "Superior Activity Reducing Anti-dsDNA at Week 37"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 46
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Joint Swelling",
      "Rheumatoid Arthritis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Reduces Joint Swelling in a Mouse Model of RA",
      "Significant Reduction in Joint Swelling Comparable to Tofacitinib",
      "Reduction in Circulating IL-12 Levels",
      "Reduction in Infiltrating Synovial IFNy+ Th1 Cells"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 47
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-579 potently degrades IRF5 across multiple preclinical species with low oral doses",
      "KT-579 completed non-GLP toxicity studies in NHP and rodents with no adverse effects at up to 200-fold predicted human efficacious exposure"
    ],
    "safety": [
      "Excellent Safety Profile"
    ],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 48
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Harnessing the powerful mechanism of TPD to develop innovative, differentiated medicines that address critical health problems in immunology",
      "Demonstrated consistent and compelling preclinical packages across our immunology programs",
      "Established unique capabilities to tackle high value undrugged targets in validated pathways linked to several diseases",
      "Advancing accelerated and innovative clinical strategies that position our programs for key inflection points near term",
      "We\u2019re always innovating for patients - advancing oral therapies with biologics-like profiles to transform treatment paradigms"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 51
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "immunological diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "first-in-industry oral degraders with biologics-like activity",
      "demonstrated compelling clinical translation of degraders\u2019 impact on clinical endpoints"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 3
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": "injectable biologics",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "inconvenient",
      "burdensome",
      "often painful for patients",
      "immunogenicity risks"
    ],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 6
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "S TAT 6",
      "I R F 5",
      "I R A K 4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 8
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRF 5",
      "IRAK 4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma",
      "COPD",
      "EoE",
      "CRSwNP",
      "CSU",
      "PN",
      "BP",
      "SLE",
      "RA",
      "UC",
      "CD",
      "Sj\u00f6grens",
      "SSc",
      "DM",
      "HS"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 9
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6",
      "IRF5",
      "IRAK4"
    ],
    "modality": "Orals with Biologics-Like Activity",
    "e3_ligase": null,
    "indications": [
      "AD",
      "HS",
      "CSU",
      "PN",
      "BP",
      "Vitiligo",
      "AA",
      "Asthma",
      "COPD",
      "CRSwNP",
      "IBD",
      "EoE",
      "RA",
      "SLE",
      "SSc",
      "Sj\u00f6gren\u2019s",
      "DM",
      "Myositis",
      "MG",
      "CIDP",
      "GD",
      "ITP"
    ],
    "therapeutic_areas": [
      "Dermatology",
      "Respiratory",
      "GI",
      "Rheumatology",
      "Other"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 10
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": "First-in-Class Oral STAT6 Degrader Program",
    "targets": [],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Dupilumab-like activity in a pill"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 12
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2b"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 19
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Adult, Moderate to Severe Eosinophilic Asthma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2b"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 20
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 21
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Median STAT6 degradation of 98% in blood in both dose groups maintained throughout the treatment period",
      "Deep skin degradation of 94% in both dose groups with multiple patients\u2019 STAT6 levels below the LLOQ (lower limit of quantification)"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 25
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Significantly Downregulated Core Type 2 Inflammation Gene Set in Skin Lesions of AD Patients"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 27
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD Patients with Comorbid Asthma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-621 achieved 56% median FeNO reduction at Day 29, exceeding dupilumab (31%) in asthma studies at week 41",
      "All 4 patients had clinically meaningful reduction in ACQ-5 (mean change of -1.2 points) and a 100% responder rate"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 31
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [
      "Well-tolerated with favorable safety at both 100 mg and 200 mg with a profile similar to what was observed in the Phase 1a healthy volunteer trial",
      "No SAEs or Severe AEs",
      "No dose-dependent pattern in the TEAEs",
      "No related TEAEs or TEAEs leading to discontinuation",
      "No AEs of conjunctivitis (or of any ocular disorder), herpes infections, or arthralgias",
      "No clinically relevant changes in vital signs, laboratory tests or ECGs"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 34
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [
      "Type 2 inflammation",
      "atopic dermatitis",
      "asthma",
      "allergic rhinitis"
    ],
    "therapeutic_areas": [
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [
      "KT-621 degraded STAT6 and blocked IL-4/13 Type 2-driven inflammation",
      "KT-621 safely and deeply degraded STAT6",
      "KT-621 demonstrated meaningful improvements on Type 2 biomarkers",
      "Results in line with or exceeded published data for dupilumab"
    ],
    "safety": [
      "safely degraded STAT6"
    ],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 35
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": "First-in-Class Oral IRF5 Degrader Program",
    "targets": [
      "IRF5"
    ],
    "modality": "Oral Degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 36
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IRF5"
    ],
    "modality": "oral small molecule",
    "e3_ligase": null,
    "indications": [
      "lupus",
      "RA",
      "SLE",
      "LN",
      "IBD"
    ],
    "therapeutic_areas": [
      "anti-inflammatory"
    ],
    "clinical_phases": [
      "Phase 1 HV start: Q1 2026",
      "Phase 1 HV data: 2H 2026"
    ],
    "claims": [
      "first-in-class",
      "potent",
      "selective",
      "fully degrades IRF5",
      "favorable safety profile"
    ],
    "safety": [
      "de-risk safety and clinical indications"
    ],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 37
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE",
      "Sj\u00f6gren\u2019s",
      "RA",
      "IBD"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "IRF5 degradation has the potential to selectively block inflammation and restore immune regulation by inhibiting pro-inflammatory cytokines, Type I IFN and autoantibody production",
      "Blocking IRF5 activity has the potential for more effective, tolerated and durable responses in autoimmune diseases"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 39
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE",
      "RA",
      "IBD",
      "SSc",
      "MS"
    ],
    "therapeutic_areas": [
      "autoimmune diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "IRF5 Genetically Validated in Multiple Autoimmune Diseases",
      "KO mice are viable and fertile; with normal B cell development",
      "IRF5 risk haplotypes and hyperactivated IRF5 levels in SLE patients associated with high serum IFN\u237a levels, anti-dsDNA or anti-RNA binding protein antibodies",
      "Genetic associations and functional variants also identified in RA, IBD, SSc, and MS",
      "IRF5 KO mouse can protect or attenuate disease in models of SLE, SSc, RA and IBD",
      "In a mouse model of lupus (FcyIIB-/-, Yaa) IRF5 plays an essential role in lupus pathogenesis, that is independent of Type I IFN pathways",
      "Meta-analyses Identified IRF5 as a Risk Locus for SLE",
      "IRF5 KO Increases Survival and has Essential Role in Lupus",
      "Type I IFN Modestly Protects Against Lupus"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 40
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE"
    ],
    "therapeutic_areas": [
      "autoimmune diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "KT-579 inhibits TLR7/8 pro-inflammatory cytokines and Type I IFN that are commonly elevated in autoimmune diseases",
      "KT-579 reduces TLR9 (CpG-B) induced plasmablast differentiation and inhibits IgG production in SLE derived B cells"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 44
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Rheumatoid Arthritis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Reduces Joint Swelling in a Mouse Model of RA",
      "Leads to Significant Reduction in Joint Swelling Comparable to Tofacitinib",
      "Reduction in Circulating IL-12 Levels",
      "Reduction in Infiltrating Synovial IFN\u03b3+ Th1 Cells"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 48
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-579 potently degrades IRF5 across multiple preclinical species with low oral doses",
      "KT-579 completed non-GLP toxicity studies in NHP and rodents with no adverse effects at up to 200-fold predicted human efficacious exposure"
    ],
    "safety": [
      "Excellent Safety Profile"
    ],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 49
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": "Partnered Oral Degrader Programs",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 50
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": "KT-485",
    "targets": [
      "IRAK4"
    ],
    "modality": "oral degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Th1-Th17",
      "Th2 Diseases"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "highly selective",
      "potent",
      "absence of any QTc signal"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 51
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": "CDK2 MG",
    "targets": [
      "CDK2"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": null,
    "indications": [
      "breast cancer",
      "solid tumors"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "selectively degrade CDK2 while sparing closely related kinases like CDK1"
    ],
    "safety": [
      "minimal impact on healthy tissue"
    ],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 52
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": "First-in-Class Oral STAT6 Degrader Program",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 55
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Compelling Preclinical Profile",
      "Potential for Dupilumab-like Activity in a Pill",
      "Exquisite Selectivity",
      "Robust Degradation in Relevant Cell Types",
      "Full Inhibition of IL-4/IL-13 Pathways, More Potent than Dupilumab",
      "STAT6 Degradation in Immune Cells",
      "IL-4 Induced TARC Release in Human PBMC",
      "Excellent Preclinical Activity Comparable or Superior to Dupilumab",
      "Lung Remodeling Goblet Cell Metaplasia in HDM Model"
    ],
    "safety": [
      "Favorable safety profile: well-tolerated in multiple preclinical species and safety studies at concentrations 40-fold above efficacious dose with up to 4 months of dosing"
    ],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 56
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 63
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "RA",
      "CAPS",
      "HS",
      "AD",
      "RP",
      "Gout",
      "Macrophage Activation Syndrome",
      "Generalized Pustular Psoriasis",
      "Asthma",
      "COPD"
    ],
    "therapeutic_areas": [
      "immune-inflammatory diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "IRAK4 degradation is the only approach to fully block the IL-1R/TLR pathway",
      "IRAK4 degradation has the potential to achieve a broad, well-tolerated anti-inflammatory effect"
    ],
    "safety": [
      "Adult humans with IRAK4 null mutation are healthy"
    ],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 64
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "CDK2",
      "CCNE"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HGSOC",
      "CDK4/6i resistant breast cancers"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CCNE1 amplification as a biomarker of dependency for CDK2",
      "High CCNE activity is associated to resistance of CDK4/6 therapies"
    ],
    "safety": [
      "CDK2 inhibitors face challenges due to similarity with other CDKs, including CDK1, causing toxicities"
    ],
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 65
    },
    "year": 2026
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 5
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": "Targeted Protein Degradation (TPD)",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 6
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 17
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "Safety",
      "PK",
      "PD"
    ],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 19
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Near Complete and Sustained IRAK4 Degradation with Multiple Daily Oral Doses (14 Days)",
      "Mean % Reduction of IRAK4",
      "Detected by mass spectrometry in circulating PBMC",
      "Steady state IRAK4 reduction achieved between Days 7 and 14",
      "Recovery towards baseline by Day 28 (2 weeks after last dose)",
      "MAD 2 through 4 approached Lower Limit of Quantitation (LLOQ)"
    ],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 34
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 39
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 44
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-413 administered on intermittent schedules leads to strong regressions in combination with the BTK inhibitor Ibrutinib",
      "KT-413 administered on intermittent schedules leads to deep and durable regressions in combination with the BCL-2 inhibitor, Venetoclax",
      "KT-413 administered on intermittent schedules leads to deep and durable regressions in combination with Rituxan"
    ],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 54
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": "IRAKIMiD Degrader KT-413",
    "targets": [
      "MYD88MT"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYD88MT DLBCL",
      "PCNSL",
      "WM"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "monotherapy",
      "combinations"
    ],
    "claims": [
      "profound antitumor activity in preclinical models both in single agent and combination",
      "clinical strategy in place to enable accelerated approval"
    ],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 57
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "T cell malignancies",
      "DLBCL",
      "AML",
      "TKI resistant oncogene-driven solid tumors"
    ],
    "therapeutic_areas": [
      "oncology",
      "immuno-oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "High degree of validation of JAK-STAT pathway in oncology and immuno-oncology supported by >25k publications",
      "Traditionally undrugged target",
      "First-in-class opportunity to address STAT3 driven pathology across large and diverse indications"
    ],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 59
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 71
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 77
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "4 hr target coverage by KT-253 is sufficient to induce apoptosis in contrast to SMIs",
      "Supports hypothesis that intermittent dosing schedule of KT-253 can drive efficacy while increasing therapeutic index"
    ],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 80
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "MDM2",
      "p53",
      "p21",
      "PUMA"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Single Dose of KT-253 Leads to Sustained Tumor Regression",
      "Single Dose of KT-253 Achieves Sustained Tumor Regression",
      "MDM2 Degradation (KT-253, 1 mg/kg) Leads to Fast Increase in p53, p21, and PUMA (Key Apoptotic Biomarker)",
      "Clinical equivalent doses of small molecule inhibitors have no significant in vivo impact in these xenograft models"
    ],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 81
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": "Targeted Protein Degradation",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 86
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "Inadequately Drugged Targets with Clear Degrader Advantage",
      "Undrugged Targets",
      "Ligandable Proteins",
      "Un-ligandable Proteins",
      "Clinically Validated Targets Enabled by E3 Ligase Tissue Restricted Expression"
    ],
    "modality": [
      "Heterobifunctional Degraders",
      "Molecular Glues"
    ],
    "e3_ligase": [
      "E3-1",
      "E3-2"
    ],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Tissue sparing or selective E3 ligases eliminate unwanted toxicity and allow full clinical potential"
    ],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 87
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "~600 unique E3 ligases",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 89
    },
    "year": 2021
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": "Oral Degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 1
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 7
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": "Small Molecule Oral Degraders",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Unlocks target classes unreachable by other modalities",
      "Achieves full pathway blockade, matching biologics-like",
      "High selectivity, strong potency, and catalytic mechanism enable full and constant target suppression with low doses/concentrations",
      "Potential to deliver the power of biologics in an oral form"
    ],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 8
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Compelling Preclinical Profile",
      "Potential for Dupilumab-like Activity in a Pill",
      "Exquisite Selectivity",
      "Robust Degradation in Relevant Cell Types",
      "Full Inhibition of IL-4/IL-13 Pathways, More Potent than Dupilumab",
      "STAT6 Degradation in Immune Cells",
      "IL-4 Induced TARC Release in Human PBMC",
      "Excellent Preclinical Activity Comparable or Superior to Dupilumab",
      "Lung Remodeling Goblet Cell Metaplasia in HDM Model"
    ],
    "safety": [
      "Favorable safety profile: well-tolerated in multiple preclinical species and safety studies at concentrations 40-fold above efficacious dose with up to 4 months of dosing"
    ],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 11
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Type 2 Diseases",
      "AD",
      "Asthma",
      "EoE",
      "CSU",
      "PN",
      "BP",
      "COPD",
      "CRSwNP"
    ],
    "therapeutic_areas": [
      "dermatology",
      "GI",
      "respiratory"
    ],
    "clinical_phases": [
      "Ph1 HV",
      "Ph1b AD",
      "Ph2b AD",
      "Ph2b Asthma",
      "Ph3"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 13
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 16
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 21
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Median STAT6 degradation of 98% in blood in both dose groups after 4 weeks of treatment",
      "Deep degradation maintained throughout dosing period",
      "Plasma PK profile at 100 and 200 mg similar to healthy volunteer study",
      "Strong translation from healthy volunteer study"
    ],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 22
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 24
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-621 Achieved Median Serum IgE Reduction of up to 14%",
      "IgE reduction comparable to dupilumab data in AD studies at week 41",
      "More robust IgE reduction often necessitates several months of pathway suppression"
    ],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 31
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Robust Serum IL-31 Reduction of up to 56%",
      "Robust reduction of pruritogenic cytokine IL-31 in both dose groups",
      "First known demonstration of IL-31 reduction in blood of AD patients in response to IL-4/13 pathway inhibition"
    ],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 32
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD Patients"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved up to 33% Reduction in FeNO in AD Patients",
      "First known demonstration of FeNO reduction in AD patients"
    ],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 33
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 34
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 35
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 37
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-621 achieved 63% Overall Mean Reduction in EASI",
      "Reductions seen as early as Day 8 and were similar across both dose groups",
      "Mean % Change from Baseline at D29 for KT-621 100 mg QD is -62%",
      "Mean % Change from Baseline at D29 for KT-621 200 mg QD is -63%",
      "Mean % Change from Baseline at D29 for KT-621 Overall is -63%"
    ],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 38
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      {
        "measure": "EASI-50",
        "response_rate": "83%",
        "dose": "KT-621 100 mg QD",
        "n": 9
      },
      {
        "measure": "EASI-50",
        "response_rate": "76%",
        "dose": "KT-621 200 mg QD",
        "n": 12
      },
      {
        "measure": "EASI-50",
        "response_rate": "67%",
        "dose": "KT-621 Overall",
        "n": 21
      },
      {
        "measure": "EASI-75",
        "response_rate": "33%",
        "dose": "KT-621 100 mg QD",
        "n": 9
      },
      {
        "measure": "EASI-75",
        "response_rate": "29%",
        "dose": "KT-621 200 mg QD",
        "n": 12
      },
      {
        "measure": "EASI-75",
        "response_rate": "25%",
        "dose": "KT-621 Overall",
        "n": 21
      },
      {
        "measure": "vIGA-AD 0/1",
        "response_rate": "22%",
        "dose": "KT-621 100 mg QD",
        "n": 9
      },
      {
        "measure": "vIGA-AD 0/1",
        "response_rate": "17%",
        "dose": "KT-621 200 mg QD",
        "n": 12
      },
      {
        "measure": "vIGA-AD 0/1",
        "response_rate": "19%",
        "dose": "KT-621 Overall",
        "n": 21
      }
    ],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 40
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-621 Achieved Robust Improvement in Patient Quality of Life (DLQI)",
      "DLQI is a measure of quality of life validated in AD",
      "Demonstrated improvements are greater than the minimum clinically important difference (MCID)"
    ],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 46
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 51
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [],
    "safety": [
      "Well-tolerated with favorable safety at both 100 mg and 200 mg with a profile similar to what was observed in the Phase 1a healthy volunteer trial",
      "No SAEs or Severe AEs",
      "No dose-dependent pattern in the TEAEs",
      "No related TEAEs or TEAEs leading to discontinuation",
      "No AEs of conjunctivitis (or of any ocular disorder), herpes infections, or arthralgias",
      "No clinically relevant changes in vital signs, laboratory tests or ECGs"
    ],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 52
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "Other Type 2 Allergic Diseases"
    ],
    "therapeutic_areas": [
      "Type 2 Inflammation",
      "Asthma",
      "Allergic Rhinitis"
    ],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [
      "Once-a-day, Oral Dosing of KT-621 Achieved Deep STAT6 Degradation in Blood and Skin",
      "Strong Effect on Disease-relevant Type 2 Inflammation Biomarkers Demonstrating IL-4/IL-13 Pathway Inhibition",
      "Dupilumab-like reductions in TARC, Eotaxin-3 and IgE",
      "Reduction of IL-31, key cytokine elevated in AD driving pruritus",
      "Dupilumab-like reductions in core Type 2 inflammation and AD disease-relevant gene sets in skin lesions",
      "First known demonstration of FeNO reduction in AD patients",
      "Robust Clinical Endpoint Impact",
      "Dupilumab-like impact on EASI, SCORAD and multiple measures of pruritus",
      "No rescue therapy required during treatment period",
      "Similar effect of KT-621 in patients with low or high baseline EASI/TARC",
      "Early evidence of activity in asthma and allergic rhinitis based on improvement in biomarkers and/or patient-reported outcomes"
    ],
    "safety": [
      "KT-621 was well tolerated",
      "Safety profile similar to results in the Phase 1a healthy volunteer trial"
    ],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 53
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [
      "Type 2 inflammation",
      "atopic dermatitis",
      "asthma",
      "allergic rhinitis"
    ],
    "therapeutic_areas": [
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [
      "KT-621 degraded STAT6 and blocked IL-4/13 Type 2-driven inflammation in vitro/in vivo as effectively as dupilumab",
      "KT-621 safely and deeply degraded STAT6, blocking IL-4/13 biomarkers equally or numerically better than dupilumab",
      "KT-621 demonstrated meaningful improvements on Type 2 biomarkers in blood and skin",
      "KT-621 demonstrated meaningful improvements on FeNO in AD and comorbid asthma patients",
      "KT-621 demonstrated meaningful improvements on clinical endpoints in patients with AD, comorbid asthma and allergic rhinitis",
      "Results in line with or in some cases numerically exceeded published data for dupilumab at week 4"
    ],
    "safety": [
      "safely and deeply degraded STAT6"
    ],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 55
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": "oral, biologics-like",
    "e3_ligase": null,
    "indications": [
      "AD",
      "asthma"
    ],
    "therapeutic_areas": [
      "Type 2"
    ],
    "clinical_phases": [
      "Phase 1b",
      "Phase 2b"
    ],
    "claims": [
      "strong translation from Phase 1a healthy volunteer trial results",
      "potential to broaden clinical access for patients",
      "disrupt a biologics-dominated Type 2 market"
    ],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 56
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 57
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": "STAT3 (KT-333)",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 7
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": "IRAKIMiD (KT-413)",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 15
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": "IRAK4 (KT-474)",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 23
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 28
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 32
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 36
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 39
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 43
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 45
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "IGA scores remained stable or improved in all patients"
    ],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 48
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 51
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 53
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 60
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD"
    ],
    "therapeutic_areas": [
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "safety, PK and PD comparable to healthy volunteers",
      "Modest, non-adverse QTcF prolongation observed",
      "Robust degradation of IRAK4 in blood and skin associated with systemic anti-inflammatory effect",
      "Promising clinical activity observed exceeding benchmark placebo rates",
      "IRAK4 degradation as a potential best in class mechanism",
      "superior clinical potential over SMI"
    ],
    "safety": [
      "Modest, non-adverse QTcF prolongation observed to spontaneously resolve back to baseline"
    ],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 61
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 63
    },
    "year": 2022
  },
  {
    "company": "kymera",
    "program": "KT-621 / STAT6 Degrader",
    "targets": [],
    "modality": "Oral Small Molecule Degrader Medicines",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 1
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Targeted Protein Degradation (TPD) leader",
      "Best-in-industry capabilities in hit finding and optimization of oral degraders",
      "Unique target selection strategy pursuing traditionally undrugged targets in highly validated pathways",
      "Portfolio poised to disrupt conventional treatment paradigms",
      "Delivering oral therapies with biologics-like profiles for the first time in industry",
      "Potential to expand access to millions of patients around the world"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 5
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "S T A T 6",
      "I R F 5",
      "I R A K 4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 7
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6",
      "IRF5",
      "IRAK4"
    ],
    "modality": "Oral Small Molecule Degraders",
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma",
      "COPD",
      "PN",
      "CRSwNP",
      "EoE",
      "BP",
      "CSU",
      "Lupus",
      "Sj\u00f6gren's",
      "RA",
      "IBD",
      "SSc",
      "DM"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "Ph1",
      "Ph1b",
      "Ph2b"
    ],
    "claims": [
      "Biomarkers in blood & skin lesions",
      "28-day efficacy",
      "Safety",
      "degradation"
    ],
    "safety": [
      "Safety"
    ],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 8
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": "TRANSCRIPTION FACTOR",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Strong genetic/clinical validation",
      "Undrugged or inadequately drugged targets",
      "Large clinical/commercial opportunities",
      "Clear path to early clinical differentiation"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 11
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma",
      "COPD",
      "PN",
      "CRSwNP",
      "EoE",
      "CSU"
    ],
    "therapeutic_areas": [
      "Allergic Th2 Inflammation"
    ],
    "clinical_phases": [],
    "claims": [
      "STAT6 is the obligate and specific transcription factor for IL-4/IL-13",
      "STAT6 targeting should phenocopy IL-4/IL-13 targeting",
      "Dupilumab generates >$14B of yearly sales, and is expected to reach $25B by 2030"
    ],
    "safety": [
      "STAT6 knock-out mouse is viable, fertile and healthy"
    ],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 12
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Only degradation is expected to match dupilumab\u2019s pathway blockade with once-a-day oral delivery"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 13
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "CSU",
      "PN",
      "BP",
      "EoE",
      "Asthma",
      "COPD",
      "CRSwNP"
    ],
    "therapeutic_areas": [
      "DERMATOLOGY",
      "GASTROENTEROLOGY",
      "RESPIRATORY"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 14
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Clinical Data Continues to Support a Dupilumab-like Profile",
      "Robust inhibition of several biomarkers, comparable/superior to published dupilumab data"
    ],
    "safety": [
      "Well tolerated at 90%+ degradation",
      "Well tolerated 16-fold above the dose with >90% degradation",
      "No SAEs",
      "No TRAEs >1 subject"
    ],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 17
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b",
      "Phase 2b"
    ],
    "claims": [
      "Potent Degradation: >90% STAT6 degradation in blood in all doses above 1.5 mg",
      "Complete STAT6 degradation achieved in both blood and skin in all doses \u22655 mg",
      "Encouraging Th2 Biomarker Impact: Results in line or superior to published data for dupilumab, with strong TARC and Eotaxin-3 reductions",
      "Excellent Tolerability: KT-621 was well-tolerated with a safety profile undifferentiated from placebo",
      "KT-621 profile surpasses Kymera\u2019s T with compelling preclinical profile human translation above expectations",
      "Proven biology of IL-4/IL-13 pathway, and clearly defined market development path, create a unique and compelling opportunity"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 18
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 20
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Single Doses of KT-621 Achieved Rapid, Deep and Prolonged STAT6 Degradation in Blood",
      "Maximal degradation seen as quickly as 4 hours after single dose",
      "Robust degradation maintained as long as 4 days after single dose with recovery by Day 14",
      "Multiple subjects with STAT6 levels below LLOQ at doses of 75 mg or greater"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 24
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Single Dose Administration of KT-621 Achieved >90% STAT6 Degradation in Blood Across All Dose Levels",
      ">95% Mean STAT6 Degradation Achieved at Doses of 75 mg or Greater"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 25
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Multiple Daily Doses of KT-621 Rapidly (8hr) Achieved Complete STAT6 Degradation in Blood",
      "Robust STAT6 degradation observed at first time point measured (8hr) for all doses above 1.5 mg",
      "Steady-state maximum degradation achieved as early as 8hr post-first dose with recovery starting at 4 days post-last dose",
      "Most subjects with STAT6 levels below LLOQ at doses of \u22655 mg"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 26
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Multiple Daily Doses of KT-621 Achieved Complete STAT6 Degradation in Skin",
      "Baseline skin STAT6 levels 5-fold lower than peripheral blood mononuclear cells (PBMC)",
      "Steady-state maximum STAT6 degradation achieved by Day 7 at doses >1.5 mg with recovery observed 14 days post-last dose"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 28
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Multiple Daily Doses of KT-621 Achieved Complete STAT6 Degradation in Skin at All Doses \u22655 mg",
      "At doses \u22655 mg, \u226595% mean STAT6 degradation was achieved with STAT6 levels below LLOQ in multiple subjects",
      "p < 0.0001 for all comparisons (KT-621 vs. Placebo)"
    ],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 29
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 30
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 34
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Asthma"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b",
      "Phase 2b"
    ],
    "claims": [
      ">90% STAT6 degradation in blood in all doses above 1.5 mg",
      "Complete STAT6 degradation achieved in both blood and skin in all doses \u22655 mg",
      "Results in line or superior to published data for dupilumab, with strong TARC and Eotaxin-3 reductions",
      "KT-621 was well-tolerated with a safety profile undifferentiated from placebo",
      "KT-621 profile surpasses Kymera\u2019s T with compelling preclinical profile human translation above expectations",
      "Proven biology of IL-4/IL-13 pathway, and clearly defined market development path, create a unique and compelling opportunity"
    ],
    "safety": [
      "KT-621 was well-tolerated with a safety profile undifferentiated from placebo"
    ],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 37
    },
    "year": 2025
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 38
    },
    "year": 2025
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3",
      "BRAF V600",
      "EGFR L858R"
    ],
    "modality": "orally bioavailable degraders",
    "e3_ligase": null,
    "indications": [
      "multiple myeloma",
      "non-Hodgkin\u2019s lymphoma",
      "melanoma",
      "colorectal cancer"
    ],
    "therapeutic_areas": [
      "oncology",
      "non-oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "40% (14/35) of Multiple Myeloma Patients With Elevated Light Chains Demonstrated at Least a 50% Decrease in dFLC",
      "69% (24/35) of patients with elevated light chain disease demonstrated a decrease in dFLC",
      "Overall geometric mean half-life estimate is approximately 2 days"
    ],
    "safety": [],
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 17
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Non-Hodgkin\u2019s Lymphoma (NHL)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 24
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma",
      "non-Hodgkin\u2019s lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "cemsidomide as a potential backbone therapy",
      "well-tolerated with a compelling safety profile",
      "compelling anti-tumor activity across a range of dose levels"
    ],
    "safety": [
      "well-tolerated",
      "compelling safety profile"
    ],
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 34
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 35
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF-V600X"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "BRAF is a serine/threonine protein kinase in the MAPK pathway that promotes cell proliferation and survival when activated through extracellular signals",
      "Constitutively active BRAF-V600X causes uncontrolled MAPK signaling, leading to tumorigenesis, tumor growth, and maintenance",
      "Decreasing BRAF-V600X activity in these cancers leads to growth arrest, cell death, and tumor regression",
      "BRAF-V600X is a clinically validated oncology target, however limitations in currently approved inhibitors highlight the need for additional BRAF-V600X targeted therapies"
    ],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 3
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF-V600X"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Specifically target mutant BRAF-V600X over wildtype BRAF",
      "Prevent mutant BRAF-V600X incorporation into RAF dimers",
      "Avoid paradoxical activation of RAF dimers",
      "Address failures in inhibitor-based therapy due to resistance mechanisms",
      "Effect deep elimination of mutant BRAF signaling and create durable responses"
    ],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 4
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF-V600E"
    ],
    "modality": "BiDAC",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT1946 Degrades BRAF-V600E in a Dose Dependent Manner",
      "HiBiT assay shows BRAF-V600E degradation with CFT1946 treatment in dose-dependent manner",
      "pERK loss aligns with loss of BRAF-V600E protein demonstrating MAPK pathway inhibition",
      "BRAF-V600E degradation with CFT1946",
      "No BRAF-V600E degradation with ligand competition, CRBN ligand competition, inhibition of CUL4 E3 with MLN4924 or inhibition of the proteasome with bortezomib"
    ],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 5
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF-V600E",
      "WT-BRAF",
      "CRAF",
      "ARAF"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 6
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT1946 Causes BRAF-V600E Degradation, Potent Inhibition of MAPK Signaling, & Loss of Viability in BRAF-V600E Cells but Not in WT-BRAF Cells",
      "BRAF-V600E Degradation by CFT1946 Causes Loss of MAPK Signaling Superior to Inhibition Alone",
      "CFT1946 Treatment of WT-BRAF Cells Has No Effect on MAPK Pathway and Cell Growth"
    ],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 7
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "non-V600E mBRAF",
      "Class II mBRAF",
      "Class III mBRAF"
    ],
    "modality": "TPD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT1946 demonstrates potential of TPD-based therapies in non-V600X mBRAF driven cancers",
      "CFT1946 provides PoC for degradation of selected non-V600E mBRAF of both Class II and Class III",
      "CFT1946 treatment of Class III mBRAF model cell line shows PoC for TPD-mediated growth inhibition superior to BRAFi",
      "CFT1946 treatment demonstrates degradation of HA-tagged mBRAF in a dose-dependent manner",
      "CFT1946 treatment of H1666 cells shows modest growth inhibition, superior to inhibition alone"
    ],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 10
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600X",
      "BRAF-V600E",
      "NRAS-Q61K"
    ],
    "modality": "BiDACTM degrader",
    "e3_ligase": null,
    "indications": [
      "BRAF-V600E\u2013driven disease",
      "BRAF-V600E/NRAS-Q61K\u2013driven model",
      "BRAF-V600X\u2013driven cancers",
      "inhibitor-resistant BRAF-V600X\u2013driven cancers"
    ],
    "therapeutic_areas": [
      "mBRAF Class II",
      "mBRAF Class III"
    ],
    "clinical_phases": [],
    "claims": [
      "potent and mutant-selective",
      "active in vitro and in vivo",
      "TPD approach could be developed"
    ],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 11
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 12
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 4
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "CRBN",
      "IKZF1",
      "IKZF3"
    ],
    "modality": "monoDAC",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 5
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 8
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 9
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 10
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "CRBN",
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT7455 is Efficacious in MM Models Resistant or Insensitive to IMiDs",
      "Reduction in CRBN Expression with Chronic IMiD Dosing",
      "CFT7455 Retains Activity in Len- & Pom-Resistant MM Cells",
      "CFT7455 Promotes Regression in Tumors Insensitive to Pom"
    ],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 16
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 18
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600E"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "BRAF V600 mutant driven solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Proof of Mechanism",
      "Proof of Degrader Concept",
      "Well tolerated and highly selective degrader",
      "No Grade \u2265 3 cutaneous adverse events",
      "Increased drug exposure observed with dose escalation",
      "Degraded BRAF V600E protein in all available post-treatment biopsies",
      "Early evidence of monotherapy anti-tumor activity in patients who progressed after treatment with BRAF inhibitors",
      "Anti-tumor activity seen across multiple BRAF V600 mutants",
      "Degradation of mutant BRAF protein overcomes resistance mechanisms",
      "Potentially deeper and more durable responses than BRAF inhibitors",
      "CFT1946 has the potential to disrupt the treatment landscape"
    ],
    "safety": [
      "Well tolerated",
      "No Grade \u2265 3 cutaneous adverse events"
    ],
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 3
    },
    "year": 2024
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 1
    },
    "year": 2026
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "Degrader",
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 8
    },
    "year": 2026
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3",
      "IRF4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "IKZF1/3 Degradation is a Clinically Validated MOA Leading to Myeloma Cell Death and T-cell Activation"
    ],
    "safety": [
      "On-target neutropenia"
    ],
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 9
    },
    "year": 2026
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "High to moderate renal clearance decreasing tolerability",
      "~50% of MM patients suffer from renal impairment",
      "Limited selectivity resulting in off-target non hematology toxicities"
    ],
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 11
    },
    "year": 2026
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR L858R"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Non-Small Cell Lung Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 20
    },
    "year": 2026
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Inflammation",
      "Neuroinflammation",
      "Neurodegeneration"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 26
    },
    "year": 2026
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": "Targeted Protein Degradation (TPD)",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Inflammation",
      "Neuroinflammation",
      "Neurodegeneration"
    ],
    "clinical_phases": [],
    "claims": [
      "Degraders have the potential to outperform inhibitors in efficacy and safety in CNS diseases",
      "Fast path to clinical proof-of-concept, including early validation based on PD markers in healthy volunteers",
      "Normalize elevated protein levels without the need for complete elimination of the target",
      "Large market opportunities with high unmet medical needs",
      "Deploying TPD where the MOA is uniquely positioned to have an advantage over inhibitors to help benefit patients in a large market"
    ],
    "safety": [],
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 28
    },
    "year": 2026
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 1
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 5
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 6
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Access to Undruggable/or Unligandable Targets",
      "MonoDAC degraders and MGDs exhibit degradation-only pharmacology",
      "Access to degrader drug candidates within more traditional Rule of 5 physicochemical property space",
      "MonoDAC Degraders and MGDs should be aligned to the right target and clinical opportunities"
    ],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 9
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 10
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 11
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 14
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 15
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 18
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 19
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "clinic"
    ],
    "claims": [
      "potent CRBN binder",
      "fast, selective degradation of IKZF1/3"
    ],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 20
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 21
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 22
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "6h0f"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 23
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target 1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "C4T MonoDAC Library has produced hits to novel MonoDAC Targets and a development candidate"
    ],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 26
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target 1",
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 27
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target 2",
      "Vinc"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Identified hit reduces tagged and endogenous Target 2 protein levels"
    ],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 29
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target 2"
    ],
    "modality": "AlphaLISA assay format",
    "e3_ligase": "CRBN-DDB1",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Biochemical screen of the MonoDAC library identifies the same hit compound"
    ],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 30
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target 2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Compound 1 demonstrates selective on-target, on-mechanism degradation of Target 2",
      "No degradation of IKZF1 or SALL4"
    ],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 31
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 32
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 33
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 1
    },
    "year": 2025
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "Degrader",
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma",
      "Non-Hodgkin\u2019s Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 6
    },
    "year": 2025
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple myeloma"
    ],
    "therapeutic_areas": [
      "Cancer"
    ],
    "clinical_phases": [],
    "claims": [
      "Degrading IKZF1/3 leads to myeloma cell death",
      "Degrading IKZF1/3 leads to T-cell activation"
    ],
    "safety": [
      "On-target neutropenia"
    ],
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 7
    },
    "year": 2025
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 10
    },
    "year": 2025
  },
  {
    "company": "c4_therapeutics",
    "program": "Project Optimus Data",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 19
    },
    "year": 2025
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 23
    },
    "year": 2025
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 29
    },
    "year": 2025
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "neuroinflammation",
      "immunology",
      "genetic disorders"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Seek first-in-class opportunities",
      "Clear and compelling advantage for a degrader over an inhibitor"
    ],
    "safety": [
      "Utilize Phase 1/2 experience with an inhibitor to inform translational and safety considerations"
    ],
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 31
    },
    "year": 2025
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IL-23/IL-17 Pathway",
      "Type 1 IFN Pathway",
      "MAPK",
      "PI3K/AKT",
      "NF-kB Pathways"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Alzheimer\u2019s Disease",
      "Psoriasis",
      "Multiple Sclerosis",
      "Down Syndrome",
      "Parkinson\u2019s Disease",
      "Rheumatoid Arthritis",
      "Multiple Myeloma",
      "Lupus Nephritis",
      "Systemic Lupus Erythematosus",
      "Inflammatory Bowel Disease",
      "Asthma",
      "Autosomal Dominant Polycystic Kidney Disease",
      "Chronic Kidney Disease",
      "Metabolic Dysfunction Associated Steatohepatitis",
      "Idiopathic Pulmonary Fibrosis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 32
    },
    "year": 2025
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Synovial Sarcoma",
      "Malignant Rhabdoid Tumor"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 6
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potent BRD9 degrader",
      "Suboptimal selectivity over BRD4",
      "Acceptable mouse IV PK profile",
      "No oral exposure"
    ],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 7
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Elimination of the linker will result in a tighter ternary complex",
      "Greater selectivity over BRD4, BRD7",
      "Smaller degraders with better properties and higher oral bioavailability"
    ],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 8
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9",
      "BRD4",
      "BRD7",
      "GSPT1",
      "IKZF1",
      "SALL4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT-8634 is a Highly Selective BRD9 Degrader",
      "Selectivity over BRD4, BRD7, and Neo-Substrates of CRBN",
      "BRD9 is the only protein significantly degraded"
    ],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 12
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8634",
    "targets": [],
    "modality": "BiDAC\u2122 degrader",
    "e3_ligase": null,
    "indications": [
      "synovial sarcoma",
      "SMARCB1-null solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [
      "CFT8634 is a potent, selective, and orally bioavailable BiDAC\u2122 degrader",
      "CFT8634 selectively inhibits the growth of BAF-perturbed cell lines",
      "CFT8634 demonstrates robust efficacy in clinically-relevant patient-derived xenograft models of synovial sarcoma"
    ],
    "safety": [],
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 17
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 1
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR"
    ],
    "modality": "Mutant Selective Degrader",
    "e3_ligase": null,
    "indications": [
      "Non-Small Cell Lung Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "EGFR"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT8919 is Active in Ba/F3 Models Expressing Secondary Mutations Resistant to Approved EGFR Inhibitors"
    ],
    "safety": [],
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 11
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "EGFR",
      "CCND1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 16
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR L858R"
    ],
    "modality": "Oral",
    "e3_ligase": null,
    "indications": [
      "EGFR L858R-driven tumors",
      "NSCLC"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Potent",
      "Allosteric",
      "Mutant-selective Degrader",
      "Active in vitro and in vivo in models with secondary mutations",
      "Demonstrates intracranial activity",
      "Clinical evaluation is warranted",
      "May combine with approved EGFR inhibitors",
      "Potential for single agent activity in the front-line setting"
    ],
    "safety": [],
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 17
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 18
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 19
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9"
    ],
    "modality": "BiDAC Degrader Approach",
    "e3_ligase": null,
    "indications": [
      "synovial sarcoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Very limited benefit of treatments for metastatic or advanced synovial sarcoma, median survival ~18 months"
    ],
    "safety": [],
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 3
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "BRD9 associates with chromatin independent of its bromodomain",
      "traditional BRD9 inhibitors do not fully ablate oncogenic transcription"
    ],
    "safety": [],
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9"
    ],
    "modality": null,
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potently degrades BRD9",
      "Selective over BRD4 & BRD7",
      "Drug-like properties",
      "Plasma stability",
      "Mouse PK"
    ],
    "safety": [],
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 11
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 15
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 18
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD4",
      "BRD7",
      "BRD9",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 21
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 23
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 29
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2",
      "Phase 1b"
    ],
    "claims": [
      "Cemsidomide 14/14 plus Dex was well tolerated",
      "demonstrated durable anti-myeloma activity at increasing dose levels",
      "A 50% ORR was observed at the highest dose of 100\u00b5g QD",
      "34% ORR observed across all dose levels",
      "TEAEs were manageable with minimal treatment discontinuations or reductions",
      "Cemsidomide has an ~2-day half-life",
      "induces potent IKZF1/3 degradation",
      "promotes CD8 T-cell activation",
      "well suited for further development across multiple lines of treatment",
      "in combination with other anti-myeloma agents"
    ],
    "safety": [
      "manageable TEAEs",
      "minimal treatment discontinuations or reductions"
    ],
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 16
    },
    "year": 2025
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600"
    ],
    "modality": "Degrader",
    "e3_ligase": null,
    "indications": [
      "Solid Tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 1
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "transcription factor",
      "chromatin modifier",
      "kinases"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "clinic"
    ],
    "claims": [
      "Designed and Advanced Degraders into the Clinic Across a Range of Target Classes, Demonstrating Robust Target Degradation",
      "Interrogated Diverse Target Classes",
      "Attained IND Clearance",
      "Achieved Desirable Drug-like Properties",
      "Degraded Target as Predicted",
      "Discovered degraders and advanced 4 INDs against a transcription factor, a chromatin modifier, and two kinases",
      "Have evaluated 3 programs in the clinic, each demonstrating robust target degradation in patients",
      "Delivered two development candidates to our collaboration partner, Biogen"
    ],
    "safety": [],
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600E"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "BRAF V600 mutant driven solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Proof of Mechanism",
      "Proof of Degrader Concept",
      "Well tolerated and highly selective degrader",
      "No Grade \u2265 3 cutaneous adverse events",
      "Increased drug exposure observed with dose escalation",
      "Degraded BRAF V600E protein in all available post-treatment biopsies",
      "Early evidence of monotherapy anti-tumor activity in patients who progressed after treatment with BRAF inhibitors",
      "Anti-tumor activity seen across multiple BRAF V600 mutants",
      "Degradation of mutant BRAF protein overcomes resistance mechanisms",
      "Potentially deeper and more durable responses than BRAF inhibitors",
      "CFT1946 has the potential to disrupt the treatment landscape"
    ],
    "safety": [
      "Well tolerated",
      "No Grade \u2265 3 cutaneous adverse events"
    ],
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "melanoma",
      "NSCLC",
      "CRC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Durable and deep responses are often not seen in melanoma, NSCLC and CRC patients, due to MAPK pathway resistance",
      "Poor tolerability, such as high-rates of cutaneous adverse events",
      "Often combined with a MEK inhibitor to enhance both efficacy and minimize side effects resulting from paradoxical activation by BRAF inhibitors",
      "Limited approved treatment options for BRAF V600 patients who do not have a BRAF V600E or V600K mutation"
    ],
    "safety": [],
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF V600 mutants"
    ],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Prevents BRAF V600 mutant mono/heterodimer formation",
      "Avoids paradoxical activation seen with approved inhibitors",
      "Addresses MAPK pathway alterations resulting from BRAF inhibitor resistance",
      "Specifically targets BRAF V600 mutations, which includes BRAF V600 mutations beyond BRAF V600E",
      "Spares wild-type BRAF, likely avoiding AEs associated with inhibition of wild-type BRAF",
      "Enables deep elimination of mutant BRAF signaling to create potential durable responses through degrader molecule recycling and catalytic effect"
    ],
    "safety": [
      "likely avoiding AEs associated with inhibition of wild-type BRAF"
    ],
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "melanoma",
      "CRC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 23
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": "small molecule approach",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "85% of proteins are currently undruggable or poorly drugged",
      "Benefits of genetic knockdown with a small molecule approach",
      "C4T\u2019s TORPEDO platform creates therapeutic candidates that have the potential to improve patient care",
      "Overcome Resistance",
      "Drug Undruggable Targets",
      "Improve Treatment Options"
    ],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 3
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 5
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 6
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 10
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 11
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target A",
      "Target B"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 12
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "CRBN",
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 14
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 15
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 16
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "MonoDAC Degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 17
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 19
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target A",
      "Target B"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 21
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target A",
      "Vinc"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Identified hit reduces tagged and endogenous Target A protein levels"
    ],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 22
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target A",
      "CRBN"
    ],
    "modality": "AlphaLISA assay format",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Biochemical screen of the MonoDAC library identifies the same hit compound"
    ],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 23
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "GSPT1",
      "IKZF1",
      "SALL4",
      "Target A"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "No degradation of IKZF1 and SALL4",
      "Compound 3 demonstrates selective on-target, on-mechanism degradation of Target A"
    ],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 24
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 26
    },
    "year": 2022
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT7455 demonstrates increased activity in vivo in comparison to CC-92480",
      "CFT7455 has longer exposure compared to CC-92480",
      "CFT7455 100 \u03bcg/kg/day resulted in durable tumor regressions for prolonged period after drug discontinuation",
      "CFT7455 was well absorbed with a plasma T1/2 of approximately 2 days",
      "Accumulation of drug was observed up to 4-fold by day 15",
      "Achieved exposures at 50 \u03bcg, which are equivalent to predicted efficacious exposures from nonclinical studies",
      "On-target neutropenia was observed, including 3 patients with Grade 4 neutropenia resulting in 2 DLTs",
      "Substantial potency and deeper degradation of the primary targets, IKZF1 and IKZF3 than initially projected at 50 \u03bcg",
      "Preliminary evidence of single agent CFT7455 activity was observed in this initial cohort of heavily pretreated MM patients, including meaningful decreases in dFLC"
    ],
    "safety": [],
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 23
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 25
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Preclinical Model Demonstrated Significant Synergy when CFT7455 is Combined with Dexamethasone",
      "CFT7455 + Dexamethasone Shows Robust Tumor Regressions Compared to Monotherapy Regimens"
    ],
    "safety": [],
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Monotherapy is well tolerated and demonstrates anti-myeloma activity and immunomodulatory effects",
      "Continuous target degradation is associated with CFT7455 dosing across all dose levels and shows anti-myeloma activity at the highest dose level",
      "14 days on/14 days off schedule provides therapeutic index with anti-myeloma activity at 75 \u00b5g",
      "Dose proportional increases in plasma exposure and long half-life of 48 hours supports 14 days on/14 days off schedule",
      "Well tolerated with manageable neutropenia in a heavily pre-treated population utilizing a 14 days on/14 days off schedule",
      "Clinical evidence of immune T-cell activation at doses below the maximum administered dose",
      "CFT7455 profile supports combination with novel MM agents and as maintenance therapy"
    ],
    "safety": [
      "well tolerated",
      "manageable neutropenia"
    ],
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 27
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455 + Dexamethasone",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "R/R MM"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 28
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 35
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma",
      "Multi-Refractory MM",
      "Early Line MM",
      "Post-Transplant MM"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Accelerated Approval in Multi-Refractory MM",
      "Numerous Approvals in Early Line MM",
      "Maintenance Approval in Post-Transplant MM"
    ],
    "safety": [],
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 37
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 39
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "melanoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT1946 exhibited dose-dependent bioavailability",
      "Proof of mechanism supported by BRAF V600E degradation as measured by change in H-score of paired biopsies from different tumor types"
    ],
    "safety": [],
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "cholangiocarcinoma",
      "non-small cell lung cancer",
      "pancreatic carcinoma",
      "small intestine cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "BRAF V600K Melanoma"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Early Evidence of Anti-Tumor Activity"
    ],
    "safety": [],
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Pancreatic Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Ongoing"
    ],
    "claims": [
      "Decrease in BRAF V600E allele fraction measured in ctDNA using WES",
      "Change in target lesion at Cycle 3: 46% decrease from baseline in SoD",
      "40% and 49% reduction in liver metastases at Cycle 3",
      "Change in target lesion at Cycle 5: 55% decrease from baseline in SoD",
      "Overall Response per RECIST 1.1 at Cycle 3: PR",
      "Overall Response per RECIST 1.1 at Cycle 5: PR"
    ],
    "safety": [],
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "melanoma",
      "colorectal cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Single agent CFT1946 has a well-tolerated safety profile",
      "Only one Grade \u22653 treatment-related adverse event",
      "No drug interruptions, reductions, or discontinuations due to treatment-related adverse events",
      "No Grade \u22653 wild-type adverse events common to BRAFi",
      "CFT1946 has demonstrated preliminary proof of mechanism",
      "Increased drug exposure observed with dose escalation",
      "Degradation of BRAF V600E protein observed in all post-treatment biopsies",
      "Evidence of anti-tumor activity observed in patients treated with CFT1946 who progressed on BRAFi",
      "8/11 patients with melanoma demonstrated tumor reduction by RECIST 1.1 criteria",
      "Activity seen in patients with BRAF V600E/K/R mutations",
      "These data support the continued development of CFT1946 as a novel approach to treat BRAF V600X solid tumors"
    ],
    "safety": [
      "Only one Grade \u22653 treatment-related adverse event",
      "No drug interruptions, reductions, or discontinuations due to treatment-related adverse events",
      "No Grade \u22653 wild-type adverse events common to BRAFi"
    ],
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF-V600X"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "BRAF-V600X is a clinically validated oncology target",
      "Decreasing BRAF-V600X activity leads to growth arrest, cell death, and tumor regression"
    ],
    "safety": [],
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 3
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF-V600X"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Specifically target mutant BRAF-V600X over wildtype BRAF",
      "Prevent mutant BRAF-V600X incorporation into RAF dimers",
      "Avoid paradoxical activation of RAF dimers",
      "Address failures in inhibitor-based therapy due to resistance mechanisms",
      "Effect deep elimination of mutant BRAF signaling and create durable responses"
    ],
    "safety": [],
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 4
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Lower mouse IV PK clearance",
      "Higher mouse oral exposure and bioavailability",
      "Generally more soluble"
    ],
    "safety": [],
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 5
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Improved Degradation Efficiency and PK",
      "Lowered mouse IV PK clearance",
      "Improved mouse oral bioavailability"
    ],
    "safety": [],
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 6
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 7
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "CRBN",
      "BRAF"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 8
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 9
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF-V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 10
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT1946 Causes BRAF-V600E Degradation, Potent Inhibition of MAPK Signaling, & Loss of Viability in BRAF-V600E Cells but Not in WT-BRAF Cells",
      "BRAF-V600E Degradation by CFT1946 Causes Loss of MAPK Signaling Superior to Inhibition Alone",
      "CFT1946 Treatment of WT-BRAF Cells Has No Effect on MAPK Pathway and Cell Growth"
    ],
    "safety": [],
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 12
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600E"
    ],
    "modality": "BiDACTM degrader",
    "e3_ligase": null,
    "indications": [
      "BRAF-V600X\u2013driven cancers",
      "inhibitor-resistant BRAF-V600X\u2013driven cancers"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "potent and mutant-selective",
      "superior to inhibitors in in vitro and in vivo models"
    ],
    "safety": [],
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 15
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 16
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Relapsed Refractory Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "First-in-Human"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Safety & Tolerability Profile"
    ],
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 17
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 31
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "2L or later",
      "4L or later"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "Accelerated Approval",
      "Full Approval"
    ],
    "safety": [
      "Characterize safety and tolerability"
    ],
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 35
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [],
    "safety": [
      "Characterize the safety and tolerability of cemsidomide in combination with a BCMA BiTE"
    ],
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 37
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 39
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "clinical"
    ],
    "claims": [
      "Leader in Delivering on the Promise of Targeted Protein Degradation",
      "Demonstrated ability to design orally bioavailable, catalytically efficient degraders that maximize the benefits of degradation",
      "Focus on targets with a clear degrader rationale",
      "Only company with both MonoDAC and BiDAC degraders in the clinic",
      "4 oncology degraders against targets of high unmet need"
    ],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 4
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": "TORPEDO Platform",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Focus on Catalytic Efficiency",
      "Optimization of overall degradation process results in maximal efficacy",
      "Ability to Design, Analyze & Predict Degrader Performance",
      "Rapid delivery of potent drug candidates through informed and efficient drug discovery",
      "Ability to Develop Both MonoDAC & BiDAC Degraders",
      "Flexibility to address different targets with tailored approach"
    ],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 5
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1/3",
      "BRD9",
      "BRAF-V600",
      "EGFR L858R"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma & Non-Hodgkin\u2019s Lymphoma",
      "Synovial Sarcoma & SMARCB1-null Cancers",
      "V600 Mutant Cancers",
      "Non-Small Cell Lung Cancer",
      "Various Cancers",
      "Various Cancers",
      "Various Cancers"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Discovery",
      "Pre-clinical",
      "Early phase development",
      "Late phase development"
    ],
    "claims": [
      "Exclusive Licensing Agreement with Betta Pharmaceuticals for the development and commercialization in Greater China"
    ],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 6
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "flat surface proteins",
      "scaffolding proteins",
      "intrinsically disordered proteins"
    ],
    "modality": "small molecule approach",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "TPD has the potential to transform the treatment of disease",
      "85% of proteins are currently undruggable or poorly drugged",
      "TPD offers a powerful modality",
      "Benefits of genetic knockdown with a small molecule approach",
      "C4T\u2019s TORPEDO platform creates therapeutic candidates that have the potential to improve patient care",
      "Overcome resistance",
      "Drug undruggable targets",
      "Improve treatment options"
    ],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 7
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": "MonoDAC degraders",
    "e3_ligase": "E3 Ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 8
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "E3 Ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 9
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "E3 Ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 10
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Chemoproteomics screening is a cellular assay that enables identification of small molecule binding sites via labeling of reactive residues on proteins.",
      "A screening campaign can provide fragment hits across the accessible reactive proteome of the chosen cell type."
    ],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 11
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 12
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "undruggable"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 13
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "undruggable"
    ],
    "modality": null,
    "e3_ligase": "E3 Ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 14
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Undruggable"
    ],
    "modality": null,
    "e3_ligase": "E3 Ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 15
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "E3 Ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 16
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 19
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 20
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 21
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "POI-21_CysX"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 22
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "POI-31_CysX",
      "POI-73_CysX"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 23
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "undruggable proteins"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 24
    },
    "year": 2023
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFRL858R"
    ],
    "modality": "Oral, CNS-Active, Allosteric Degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Orally bioavailable, selective, allosteric degrader of EGFR L858R",
      "Active in vitro and in vivo in models with secondary mutations",
      "Demonstrates intracranial activity",
      "Potential to be active as single agent in the frontline setting"
    ],
    "safety": [],
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 16
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "Monofunctional Degradation Activating Compound (MonoDAC)",
    "e3_ligase": "CRBN",
    "indications": [
      "myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Class-leading catalytic activity to enable potent, rapid, and deep target degradation",
      "High binding affinity to overcome IMiD resistance",
      "Selective to reduce off-target liabilities",
      "Optimized pharmacologic profile to enable sustained IKZF1/3 degradation"
    ],
    "safety": [],
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "R/R MM",
      "non-Hodgkin lymphoma"
    ],
    "therapeutic_areas": [
      "MM"
    ],
    "clinical_phases": [
      "first-in-human"
    ],
    "claims": [
      "High CRBN binding affinity (Kd = 0.9 nM)",
      "Rapid, deep degradation of IKZF1/3 that is associated with apoptosis",
      "Broad, potent antiproliferative activity in a panel of MM cell lines",
      "Regression in multiple treatment-na\u00efve MM tumor models at doses \u226510 \u00b5g/kg/day",
      "Durable antitumor responses consistent with long-lived pharmacodynamic activity",
      "Efficacy in models unresponsive to approved IMiDs",
      "Expected efficacy and survival outcomes when combined with dexamethasone"
    ],
    "safety": [
      "safety and tolerability of CFT7455"
    ],
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "ongoing": {
          "count": 3,
          "percentage": 13
        },
        "discontinued": {
          "count": 20,
          "percentage": 87,
          "reasons": {
            "progressive_disease": 14,
            "physician_decision": 3,
            "adverse_event": 2,
            "death": 1
          }
        }
      }
    ],
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 5
    },
    "year": 2024
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "PK Was Dose-Proportional With an ~2-day Half-life",
      "Plasma exposure of cemsidomide monotherapy was dose-proportional",
      "The overall geometric mean half-life estimate is approximately 2 days"
    ],
    "safety": [],
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 8
    },
    "year": 2024
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "peripheral T-cell lymphoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Cemsidomide displays a differentiated PK profile with an approximately 2-day half life",
      "Cemsidomide was well tolerated",
      "Cemsidomide as a single agent demonstrated compelling anti-lymphoma activity"
    ],
    "safety": [
      "2 DLTs were observed at 100 \u00b5g (grade 4 thrombocytopenia)",
      "Grade 3/4 neutropenia cases were manageable with no cases resulting in discontinuation"
    ],
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 21
    },
    "year": 2024
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 22
    },
    "year": 2024
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": "PROTAC\u00ae",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Eliminate (rather than inhibit) disease-causing proteins",
      "High specificity without the requirement for strong binding",
      "Disrupt scaffolding functions of target proteins",
      "Bind and degrade classically 'undruggable' proteins",
      "Act iteratively (catalytically)",
      "Be delivered orally and achieve broad tissue distribution, including across the blood-brain-barrier"
    ],
    "safety": [],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 3
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "One program in a Phase 3 study, and two drug candidates in Phase 2",
    "targets": [],
    "modality": "PROTAC\u00ae degraders",
    "e3_ligase": null,
    "indications": [
      "oncology",
      "neuroscience"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 3",
      "Phase 2"
    ],
    "claims": [
      "Consistent ability to create PROTAC\u00ae degraders with drug-like properties and signals of clinical efficacy and tolerability"
    ],
    "safety": [],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "Estrogen Receptor (ER)"
    ],
    "modality": "PROTAC\u00ae",
    "e3_ligase": null,
    "indications": [
      "advanced breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "First-in-class Estrogen Receptor (ER)-degrading PROTAC\u00ae",
      "ARV-471 has the potential to become an oral, best-in-class targeted therapy",
      "ARV-471 demonstrated superior ER degradation (>90%) and superior tumor regression versus fulvestrant",
      "ARV-471 is a potent degrader of ER as well as a complete ER antagonist",
      "Very promising efficacy and tolerability profile to date"
    ],
    "safety": [],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "Excellent tolerability and signals of efficacy in the most heavily pretreated patients of any ER-targeting therapy",
      "demonstrated strong signals of efficacy in the VERITAC Phase 2 trial",
      "Clinical Benefit Rate (Phase 2): 38% (All patients), 51% (Patients with ESR1 mutant tumors)",
      "Progression-Free Survival (Phase 2): 3.7 Months (All patients), 5.7 Months (Patients with ESR1 mutant tumors)",
      "ARV-471 has been well tolerated"
    ],
    "safety": [
      "Grade 3/4 TRAE reported in 6% (2/35) patients at 200 mg",
      "In 35 patients treated at the recommended Phase 3 dose (200 mg), no dose reduction and 1 discontinuation"
    ],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "VERITAC-21",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [
      "ARV-471 degrades ESR1mut and ESR1wt equally",
      "ARV-471 has already demonstrated signals of efficacy in both ESR1 mutant and wild-type patients",
      "In CDK4/6 inhibitor-pretreated patients, ER therapies appear to have greater activity in ESR1 mutant tumors",
      "In the VERITAC Ph 2 trial, less-pretreated 2L patients had a numerically higher clinical benefit rate"
    ],
    "safety": [],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Metastatic Castrate Resistant Prostate Cancer (mCRPC)",
      "Castrate Sensitive Prostate Cancer",
      "Biochemical / Recurrent Prostate Cancer",
      "non-mCRPC"
    ],
    "therapeutic_areas": [
      "Prostate Cancer"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "46% PSA50 response rate in patients with AR T878X/H875Y-positive tumors",
      "0% Grade \u22654 TRAEs",
      "Low rates of discontinuation and dose reduction"
    ],
    "safety": [
      "manageable tolerability"
    ],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "PROTAC\u00ae",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "oncology",
      "neurodegenerative disease"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "first-in-human"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "BCL6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Diffuse Large B-Cell Lymphoma (DLBCL)"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "first-in-class potential therapy for Diffuse Large B-Cell Lymphoma (DLBCL)",
      "BCL6 is genetically mutated in up to 85% of DLBCL",
      "More than 18,000 people are diagnosed with DLBCL each year",
      "DLBCL is largely devoid of oral options",
      "there is no BCL6-targeted therapy on the market or in the clinic"
    ],
    "safety": [],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 15
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "mutant huntingtin"
    ],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [
      "neurological diseases"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Cross the blood-brain barrier",
      "Reach targets in 'deep brain' regions",
      "Degrade disease-causing proteins inside cells",
      "Differentiate between mutant and wild-type proteins"
    ],
    "safety": [],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 17
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": "PROTAC\u00ae-induced LRRK2 degradation",
    "e3_ligase": null,
    "indications": [
      "Parkinson\u2019s Disease"
    ],
    "therapeutic_areas": [
      "neurodegenerative disease"
    ],
    "clinical_phases": [],
    "claims": [
      "No disease-modifying therapies have been approved for PD"
    ],
    "safety": [],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 18
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "oral PROTAC\u00ae clinical candidate",
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "GLP toxicity studies"
    ],
    "claims": [
      ">85% LRRK2 degradation in deep brain regions of cynomolgus monkeys after oral dosing",
      "87% decrease in Cortex",
      "89% decrease in Striatum",
      "87% decrease in Cerebellum"
    ],
    "safety": [],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 19
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "breast cancer",
      "prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology",
      "neuroscience"
    ],
    "clinical_phases": [
      "pivotal trials",
      "first-in-human studies"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 20
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 21
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "cancer",
      "neurodegenerative diseases"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 3
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "E3 ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 4
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": "vepdegestrant",
    "targets": [
      "ESR1"
    ],
    "modality": "PROTAC ER degrader",
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- advanced breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "best-in-class treatment",
      "5-month median PFS",
      "2.9-month improvement over fulvestrant"
    ],
    "safety": [],
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 6
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 7
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "cancer",
      "neurodegenerative diseases"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 20
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [
      "androgen receptor"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "first PROTAC degrader with an efficacy signal in humans",
      "first evidence for androgen receptor degradation in patients"
    ],
    "safety": [
      "generally well tolerated",
      "dose escalation continues"
    ],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 3
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 4
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": "PROTAC\u00ae",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "First proof of concept for PROTAC\u00ae protein degraders",
      "Benefitting patients where traditional inhibitors have failed",
      "Validates our confidence in this novel therapeutic modality and our pipeline"
    ],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 5
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": "ARV\u2010110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 6
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": "PROTAC\u00ae protein degraders",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Will a PROTAC be safe in humans?"
    ],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 10
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 11
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 13
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "patient": 1,
        "toxicity": "Grade 3/4 ALT/AST and renal failure"
      },
      {
        "patient": 2,
        "toxicity": "Grade 3 ALT/AST"
      }
    ],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 15
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV\u2010110\u2019s exposures are dose\u2010proportional and continue to demonstrate drug\u2010like pharmacokinetics",
      "half\u2010life supports QD dosing",
      "T1/2 ~ 110 hours"
    ],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 16
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "AR"
    ],
    "modality": "PROTAC\u00ae protein degraders",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Decreased AR protein levels in an AR wildtype/amplified tumor from a patient following 6 weeks of ARV-110 dosing (280 mg)"
    ],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 17
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "L702H",
      "AR-V7",
      "T878S",
      "W742C",
      "T878A",
      "H875Y"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Confirmed PSA50 responses",
      "Confirmed RECIST response"
    ],
    "safety": [
      "Excluding one patient with DLT associated with rosuvastatin"
    ],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 20
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Confirmed PSA responder; non-evaluable by RECIST",
      "PSA: 74% decline",
      "No radiographic progression",
      "Duration of ARV-110: 30 weeks and ongoing"
    ],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 21
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Unequivocal efficacy signal in first-in-human dose escalation study",
      "Deep, durable, and ongoing responses",
      "Heavily pretreated population",
      "Patients resistant to standard of care",
      "Favorable safety profile",
      "Tolerability consistent with 2nd generation AR therapies",
      "Manageable drug-drug interaction with breast cancer resistant pump substrates",
      "420 mg cohort dosed",
      "Backfilling patients at 280 mg while dose escalating",
      "Adding new sites for Phase 2 expansion",
      "AR mutational profile of responders suggests a potential patient selection strategy and accelerated approval path"
    ],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 23
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 24
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": "ARV\u2010110",
    "targets": [],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Preclinical profile translating into clinical benefit",
      "Signals of efficacy in a heavily pretreated patient population with high unmet need, where traditional inhibitors have failed",
      "Proves the concept of PROTAC targeted protein degradation, validating our confidence in our pipeline of degraders",
      "Arvinas is strongly positioned to deliver on milestones in 2020 and beyond"
    ],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 26
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 27
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 28
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": "PROTAC protein degraders",
    "e3_ligase": "E3 Ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 29
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 30
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "estrogen receptor"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "breast cancer",
      "late-line metastatic castrate-resistant prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "best-in-class estrogen receptor-targeting therapy"
    ],
    "safety": [
      "demonstrated safety and efficacy"
    ],
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+ Breast Cancer"
    ],
    "therapeutic_areas": [
      "Breast Cancer"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+ breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Compelling efficacy signal in heavily pretreated patients",
      "Potential for 2L/3L approval as a monotherapy or combination",
      "Well tolerated, with manageable adverse events",
      "Superior ER degradation compared to SERDs",
      "Initiated combinations with CDK4/6 inhibitors in metastatic ER+ breast cancer",
      "Opportunity to pursue development in the neoadjuvant and adjuvant (pre- and post-surgery) settings",
      "Potential future endocrine backbone therapy of choice in both adjuvant and metastatic settings",
      "ER+ breast cancer represents an addressable population of >200k patients per year in the US alone"
    ],
    "safety": [
      "Well tolerated, with manageable adverse events"
    ],
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 11
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "oncology",
      "I-O",
      "neuroscience"
    ],
    "clinical_phases": [],
    "claims": [
      "Validates our high confidence in the future success of ARV-471",
      "Accelerates and broadens the development and potential commercialization of ARV-471",
      "Augments build-out of a fully integrated company to support progression of other clinical programs, including ARV-110",
      "Adds resources to advance our deep pipeline in oncology, I-O, and neuroscience"
    ],
    "safety": [],
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 1
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 3
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "estrogen receptor"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Potential best-in-class estrogen receptor-targeting therapy",
      "Outstanding tolerability profile observed",
      "Better ER degradation than fulvestrant and clinical-stage SERDs",
      "Robust signals of efficacy in a patient population expected to have highly ER-independent disease",
      "42% clinical benefit rate"
    ],
    "safety": [
      "Outstanding tolerability profile observed"
    ],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [
      "breast cancer"
    ],
    "clinical_phases": [],
    "claims": [
      "endocrine backbone of choice",
      "safe",
      "high-potency ER degrader"
    ],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "First-in-Human"
    ],
    "claims": [],
    "safety": [
      "Safety and tolerability"
    ],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 9
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- advanced breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "high rate of ER-independent resistance",
      "Believed to be the only trial of an ER-targeting therapy requiring prior CDK4/6 treatment",
      "Outcomes are poor following CDK4/6 inhibitor therapy, e.g., for fulvestrant: Median PFS = 1.8 months, CBR estimated \u226420%"
    ],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "adverse_event": "Nausea",
        "grade_1": 2,
        "grade_2": 1
      },
      {
        "adverse_event": "Arthralgia",
        "grade_1": 4,
        "grade_2": 1
      },
      {
        "adverse_event": "Fatigue",
        "grade_1": 2,
        "grade_2": 2
      },
      {
        "adverse_event": "Decreased appetite",
        "grade_1": 3,
        "grade_2": 0
      }
    ],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-471\u2019s PK is dose proportional",
      "exposures far exceed preclinical efficacy thresholds",
      "Effective half-life (T1/2) ~~ 28 hours"
    ],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-471 degraded ER up to 90% through the 120 mg dose level",
      "Degradation up to 90%; average of 62%",
      "Degradation superior to fulvestrant (previously reported: 40-50%)",
      "Degradation of wild type ER and ESR1 mutant proteins"
    ],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 15
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Confirmed RECIST Partial Response (cPR) in a patient with extensive prior therapy and an ESR1 mutation at 120 mg",
      "51% reduction in target lesions (RECIST partial response)"
    ],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 16
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2-breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Superior degradation to fulvestrant and SERDs",
      "Strong efficacy signal in a predominantly ER-independent population",
      "Well tolerated",
      "Potential for 2L/3L approval as monotherapy or in combination",
      "Planned combinations with CDK4/6 inhibitors in adjuvant or early metastatic cancers"
    ],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 22
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 23
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "40% PSA50 in a molecularly defined subgroup",
      "well tolerated",
      "40% PSA50 in T878/H875 patients",
      "additional activity in wild-type tumors"
    ],
    "safety": [
      "well tolerated",
      "escalating through the current dose of 700 mg"
    ],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 24
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 25
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "90% PSA80",
      "8-15% PSA50",
      "<10%"
    ],
    "safety": [
      "High tumor heterogeneity",
      "Resistance mechanisms"
    ],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 26
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-110 is showing early clinical benefit in highly refractory patients",
      "Median prior therapies: 5",
      "76% Patients treated with prior chemotherapy",
      "82% Patients treated with both abiraterone and enzalutamide",
      "84% Patients with non-AR mutations",
      "Existing AR-directed therapies expected to be ineffective",
      "High tumor heterogeneity suggests low dependence on AR"
    ],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 27
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARDENT Phase 2",
    "targets": [],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "Promising antitumor activity in heavily pre-treated patients with limited treatment options",
      "PSA reduction is associated with plasma exposure",
      "AR molecular profiling identifies a molecularly defined, late line population that may have greatest response to ARV-110",
      "Activity in wild-type AR patients supports broader use",
      "ARV-110 is well tolerated, allowing continued dose escalation up to current dose of 700 mg daily, and potentially supporting use in earlier lines of therapy"
    ],
    "safety": [
      "Safety cut-off date: October 2, 2020"
    ],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 28
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 29
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Increased ARV-110 clinical activity at higher exposures",
      "This threshold is based on preclinical efficacy in a standard prostate cancer model",
      "This threshold is based on preclinical efficacy in an enzalutamide-resistant prostate cancer model",
      "Exposure-activity relationship informs and supports Phase 2 dose selection"
    ],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 30
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "We have identified ARV-110-sensitive populations despite significant tumor heterogeneity in our patient population",
      "Genomic alterations are known to increase over time and with multiple treatments in mCRPC",
      "Treatment-refractory progression in mCRPC",
      "Treatment-naive progression",
      "Genetic context, an important determinant of response, is the basis for our Phase 2 patient selection strategy",
      "The tumors of patients in our Phase 1 dose escalation are highly heterogeneous",
      "84% have non-AR mutations",
      "Potential for high AR-independence",
      "<10% PSA response expected"
    ],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 31
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [
      "wild-type AR"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "refractory mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Best PSA Change In Patients with Wild-Type AR (N=15)",
      "PSA50 13% (2/15)"
    ],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 34
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARDENT Phase 2 expansion trial",
    "targets": [],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Well tolerated; no TRAEs Gr >2",
      "Strong signal in molecularly defined patient populations",
      "High potential for patient benefit in earlier-line, more AR-dependent patients"
    ],
    "safety": [
      "Safety cut-off date: October 2, 2020"
    ],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 35
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC",
      "AR mutant patients"
    ],
    "therapeutic_areas": [
      "prostate cancer"
    ],
    "clinical_phases": [
      "Confirmatory Phase 3",
      "Pivotal Phase 2"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 37
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC",
      "CSPC"
    ],
    "therapeutic_areas": [
      "prostate cancer"
    ],
    "clinical_phases": [],
    "claims": [
      "Driving tumor responses and PSA reductions in a molecularly defined, late-line mCRPC population",
      "Late-line activity suggests strong potential in CSPC",
      "Well tolerated",
      "Two potential registrational paths",
      "Accelerated approval in molecularly defined mCRPC",
      "Broader 1L/2L mCRPC",
      "High unmet need across all stages of prostate cancer",
      "Addressable patient population of >250K per year in the US alone translates into a >$8B market opportunity"
    ],
    "safety": [
      "Well tolerated"
    ],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 38
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 39
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 41
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "registrational studies"
    ],
    "claims": [
      "Goal to have first PROTAC\u00ae degraders proven to benefit patients in registrational studies",
      "Sustainably nominating \u22651 clinical candidate per year",
      "PROTAC Discovery Engine delivering candidates with tissue- and disease-specific degradation",
      "Completing build-out of the resources and capabilities to bring PROTAC therapeutics to market"
    ],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 42
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 43
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Robust signals of efficacy and manageable tolerability of bavdegalutamide support a potential path to accelerated approval",
      "Data to date demonstrated AR T878X/H875Y mutations correlated with high tumor responsiveness to bavdegalutamide",
      "46% PSA50 in all patients with AR T878X/H875Y tumor mutations",
      "2 of 7 RECIST evaluable patients with durable confirmed partial responses; 6 of 7 patients with tumor reductions",
      "PSA declines and RECIST responses in tumors without AR T878X/H875Y mutations suggest an opportunity to develop bavdegalutamide more broadly in prostate cancer",
      "Bavdegalutamide has a manageable tolerability profile",
      "The majority of TRAEs are Grade 1 or 2; no Grade \u22654 TRAEs",
      "Low rates of discontinuation or dose reduction from the RP2D due to TRAEs",
      "Potential accelerated path to market via companion diagnostic approach in post-NHA patients; goal of initiating pivotal trial by year end 2022"
    ],
    "safety": [
      "The majority of TRAEs are Grade 1 or 2; no Grade \u22654 TRAEs",
      "Low rates of discontinuation or dose reduction from the RP2D due to TRAEs"
    ],
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 3
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [
      "prostate cancer"
    ],
    "clinical_phases": [],
    "claims": [
      "Post-NHA treatment in earlier-line settings",
      "Novel therapies for 2L/3L patients"
    ],
    "safety": [],
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [
      "wild-type AR",
      "AR T878X",
      "AR H875Y"
    ],
    "modality": "oral PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "promising efficacy profile",
      "40% of patients with AR T878X/H875Y mutations had PSA reductions >50%",
      "one patient with confirmed partial response"
    ],
    "safety": [
      "76% of patients received prior chemotherapy",
      "82% received both abiraterone and enzalutamide",
      "84% had non-AR gene mutations"
    ],
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [
      "prostate cancer"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "safety and tolerability of bavdegalutamide acceptable for use in a post-NHA mCRPC patient population",
      "efficacy signal sufficiently robust (>25% PSA50) in tumors with AR T878X/H875Y mutations to support potential for accelerated approval",
      "less pretreated, post-NHA patient population have more AR-driven disease leading to a higher PSA response rate for bavdegalutamide"
    ],
    "safety": [],
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "safety and tolerability of bavdegalutamide acceptable for use in a post-NHA mCRPC patient population",
      "efficacy signal sufficiently robust (>25% PSA50) in tumors with AR T878X/H875Y mutations",
      "less pretreated, post-NHA patient population have more AR-driven disease leading to a higher PSA response rate for bavdegalutamide"
    ],
    "safety": [
      "acceptable for use in a post-NHA mCRPC patient population"
    ],
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 10
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "46% PSA50 in all patients with AR T878X/H875Y tumor mutations",
      "PSA50=46%",
      "PSA30=57%"
    ],
    "safety": [],
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 12
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Bavdegalutamide showed robust duration of treatment in Phase 1 and ARDENT trial patients with AR T878X/H875Y mutant tumors",
      "12 (43%) patients received bavdegalutamide for \u226524 weeks",
      "9 patients remaining on treatment at data cutoff"
    ],
    "safety": [],
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Durable partial responses in 2 of 7 RECIST-evaluable patients with AR T878X/H875Y mutant tumors",
      "Activity was durable",
      "patients with confirmed partial responses (PR) remained on treatment for approximately 9 (ongoing) and 10 months",
      "6 of 7 patients had tumor reductions"
    ],
    "safety": [],
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 14
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "PSA50 rate: 46%",
      "Durable partial responses: 2 of 7",
      "Tumor regression: 6 of 7"
    ],
    "safety": [],
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 15
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "safety and tolerability of bavdegalutamide acceptable for use in a post-NHA mCRPC patient population",
      "efficacy signal sufficiently robust (>25% PSA50) in tumors with AR T878X/H875Y mutations to support potential for accelerated approval",
      "less pretreated, post-NHA patient population have more AR-driven disease leading to a higher PSA response rate for bavdegalutamide"
    ],
    "safety": [
      "acceptable for use in a post-NHA mCRPC patient population"
    ],
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 17
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "The ARDENT trial is evaluating the efficacy of bavdegalutamide in a subgroup of 'less pretreated' patients",
      "This population would have fewer AR-independent alterations and be more responsive to bavdegalutamide"
    ],
    "safety": [],
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 18
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 19
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "Robust signals of clinical activity in heavily pretreated patients with mCRPC who received 1\u20132 prior novel hormonal agents; supports potential path to accelerated approval",
      "46% PSA50 rate in patients with AR T878X/H875Y mutant tumors",
      "2 of 7 RECIST-evaluable patients with durable partial responses",
      "6 of 7 patients with tumor reductions",
      "43% of patients remained on treatment for 24 weeks or more",
      "Manageable tolerability profile",
      "Plans to explore bavdegalutamide in an earlier-stage, broader patient population",
      "Anticipate initiating a pivotal trial in patients with T878/H875 mutant tumors by year end 2022"
    ],
    "safety": [
      "Manageable tolerability profile"
    ],
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 22
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": [
      "vepdegestrant",
      "bavdegalutamide",
      "luxdegalutamide (JSB462)",
      "ARV-102",
      "ARV-393",
      "ARV-806"
    ],
    "targets": [],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "breast cancer"
    ],
    "therapeutic_areas": [
      "neuroscience",
      "oncology"
    ],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [
      "Potentially first to market in breast cancer",
      "Positive Phase 3 topline readout"
    ],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 4
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "E3 ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 6
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Neurology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Its safety and effectiveness have not been established."
    ],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 11
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "mutant proteins",
      "wild-type proteins"
    ],
    "modality": "PROTAC degraders",
    "e3_ligase": null,
    "indications": [
      "neurodegenerative diseases"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "preclinical",
      "clinical"
    ],
    "claims": [
      "orally administered",
      "selectively target mutant and/or wild-type proteins",
      "dose-dependent increases in exposure in cerebral spinal fluid after single and multiple doses of ARV-102 indicated brain penetration"
    ],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 13
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "Parkinson\u2019s disease",
      "Progressive Supranuclear Palsy"
    ],
    "therapeutic_areas": [
      "Neuroinflammation"
    ],
    "clinical_phases": [],
    "claims": [
      "LRRK2 single nucleotide polymorphisms are associated with elevated LRRK2 levels in patients with Parkinson\u2019s disease and Progressive Supranuclear Palsy"
    ],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 16
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": "orally dosed",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-102 degrades LRRK2 in NHP deep-brain regions",
      "CSF levels of LRRK2 track cortex LRRK2",
      "Orally dosed ARV-102 reaches multiple deep brain regions in NHPs and degrades LRRK2 up to 94%",
      "In NHPs, CSF levels of LRRK2 can be used to indicate levels of LRRK2 in cortex"
    ],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 20
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-102 induced dose-dependent reductions in LRRK2 levels in CSF",
      ">50% LRRK2 reduction at single doses \u226560 mg",
      "repeated doses \u226520 mg"
    ],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 23
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Parkinson\u2019s"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-102 exposure in plasma and CSF increased in a dose-dependent manner",
      "indicating brain penetration"
    ],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 26
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": "ARV-027",
    "targets": [
      "polyQ-AR"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Neurology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 29
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-027 induced polyQ-AR degradation in muscle tissues and rescued strength and endurance",
      "Degradation of monomeric polyQ-AR ranged from 43-63%"
    ],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 33
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [
      "BCL6"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Hematology-Oncology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Its safety and effectiveness have not been established."
    ],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 34
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 36
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "PTPN6",
      "IRF4",
      "CDKN1B"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "BCL6 degradation by ARV-393 drives antitumor activity by increasing gene expression normally repressed by BCL6",
      "BCL6 is a transcriptional repressor and expression of PTPN6, IRF4, and CDKN1B are repressed by it",
      "Treatment with ARV-393 increased the expression of PTPN6, IRF4, and CDKN1B, indicating BCL6 pathway engagement, collectively driving antitumor effects"
    ],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 41
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "CD19",
      "CD79b",
      "CD20",
      "CD20xCD3",
      "BTK",
      "BCL2",
      "EZH2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "non-Hodgkin lymphoma",
      "DLBCL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-393 has the potential to be an attractive combination partner for development of novel treatment options for non-Hodgkin lymphoma",
      "In preclinical models of aggressive DLBCL, ARV-393 demonstrated broad combinability, with tumor regressions observed in combination with SOC chemotherapy, SOC biologics and investigational oral small molecule inhibitors targeting clinically validated oncogenic drivers of lymphoma"
    ],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 44
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed/refractory non-Hodgkin lymphoma",
      "relapsed/refractory mature B-cell NHL",
      "nTFHL-AI"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "safety",
      "tolerability",
      "pharmacokinetics (PK)",
      "pharmacodynamics (PD)",
      "preliminary antitumor activity"
    ],
    "safety": [
      "Dose may be escalated to higher dose cohorts or de-escalated to lower dose cohorts based on the safety and tolerability as per a Cohort Review Committee recommendation"
    ],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 47
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": "ARV-806",
    "targets": [
      "KRAS G12D"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Its safety and effectiveness have not been established."
    ],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 48
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Pancreatic ductal adenocarcinoma",
      "Colorectal carcinoma",
      "Non-small cell lung cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 51
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "KRAS G12D mutated advanced solid tumors",
      "previously treated KRAS G12D mutated advanced PDAC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [
      "safety",
      "tolerability",
      "pharmacokinetics (PK)",
      "preliminary antitumor activity"
    ],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 58
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "2L+",
      "ESR1 mutant setting"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "BEST-IN-CLASS TREATMENT without tradeoffs between efficacy, tolerability, and patient reported outcomes",
      "Favorable safety/tolerability profile",
      "Low rates and severity of GI-related events",
      "Low rate of discontinuation (2.9%)",
      "Patient characteristics of those enrolled in VERITAC-2 were representative of real-world 2L setting",
      "100% prior CDK4/6i + ET, pre/peri menopausal",
      "~2.4x Improvement in mPFS over fulvestrant",
      "Improvement in mPFS (5.0m vs. 2.1m) vs. fulvestrant"
    ],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 62
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ESR1 mutations"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "The risk of clinically meaningful deterioration in pain was significantly lower with vepdegestrant compared to fulvestrant across all pain measures evaluated in patients with ESR1 mutations"
    ],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 69
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": "vepdegestrant",
    "targets": [
      "ESR1"
    ],
    "modality": "PROTAC ER degrader",
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- advanced or metastatic breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "2L+"
    ],
    "claims": [
      "best-in-class treatment",
      "5-month median PFS",
      "2.9-month improvement over fulvestrant"
    ],
    "safety": [],
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 70
    },
    "year": 2025
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-471 degraded ER up to 90% through the 120 mg dose level",
      "average degradation of 62%",
      "68% Reduction in ER after treatment with 60 mg ARV-471"
    ],
    "safety": [],
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 10
    },
    "year": 2021
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Confirmed RECIST Partial Response in a patient with extensive prior therapy and an ESR1 mutation at 120 mg",
      "51% reduction in target lesions (RECIST partial response) after 4 cycles of ARV-471"
    ],
    "safety": [],
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 11
    },
    "year": 2021
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- Breast Cancer"
    ],
    "therapeutic_areas": [
      "Breast Cancer"
    ],
    "clinical_phases": [
      "Early Breast Cancer Enabling trial in neoadjuvant setting",
      "Phase 1b",
      "VERITAC Phase 2 Expansion trial",
      "Phase 1b"
    ],
    "claims": [
      "ARV-471 or ARV-471 + CDK4/6i (palbociclib)",
      "ARV-471 + CDK4/6i (palbociclib)",
      "ARV-471",
      "ARV-471 + everolimus"
    ],
    "safety": [],
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 12
    },
    "year": 2021
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC",
      "Castration-sensitive Prostate Cancer"
    ],
    "therapeutic_areas": [
      "prostate cancer"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "Accelerated Approval"
    ],
    "safety": [],
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 17
    },
    "year": 2021
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "E3 KnowledgeBase \u2013 matching the correct E3 ligase to correct target",
      "Leveraging AI and structural understanding of ligases to identify and design ligands; deal with Insilico Medicine expands AI capabilities",
      "Arvinas\u2019 DNA-encoded libraries for advanced screening",
      "Identification of new \u201cwarheads\u201d for previously undruggable targets",
      "Zone of Ubiquitination \u2013 we design PROTAC degraders to predict the precise location where a protein can be tagged",
      "Predictive computational modeling",
      "State-of-the-art proteomics capabilities",
      "\u201cArvinas Rules\u201d for drug-like properties, including blood-brain barrier penetration and oral bioavailability in humans",
      "Deep knowledge of molecular features allow us to create PROTAC degraders with drug-like properties and activities"
    ],
    "safety": [],
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 18
    },
    "year": 2021
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "plant",
      "fungi",
      "insect"
    ],
    "modality": "PROTAC\u00ae technology",
    "e3_ligase": "fungi-exclusive ligase binder",
    "indications": [
      "weed control",
      "disease control",
      "insect control"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Effective as herbicides",
      "Active in multiple fungi",
      "Effective in aphid assay",
      "Target site engagement validated, and phenotypes observed",
      "Demonstrated ability to overcome uptake & metabolism challenges"
    ],
    "safety": [
      "previously shelved due to crossover plant phytotoxicity"
    ],
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 23
    },
    "year": 2021
  },
  {
    "company": "arvinas",
    "program": "ARV-766",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "interim Phase 2"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 1
    },
    "year": 2023
  },
  {
    "company": "arvinas",
    "program": "ARV-766",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC",
      "CSPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-766 is showing promising efficacy signals in late-line mCRPC",
      "ARV-766 is well-tolerated",
      "42% of patients with AR LBD mutations achieved PSA50",
      "3 of 3 patients with co-occurring AR T878/H875/L702H mutations achieved PSA50",
      "Two of four RECIST-evaluable patients with AR LBD mutations achieved partial responses (1 confirmed, 1 unconfirmed)",
      "Majority of treatment related adverse events (TRAEs) are Grade 1 or 2, with no Grade \u22654 TRAEs",
      "Low rates of discontinuation or dose reduction",
      "Emerging efficacy signals and tolerability profile support continued development in mCRPC and CSPC"
    ],
    "safety": [
      "ARV-766 has been well tolerated to date"
    ],
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 3
    },
    "year": 2023
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      {
        "AR LBD Mutations": {
          "percentage": 28,
          "count": 13,
          "total_patients": 47
        }
      }
    ],
    "safety": [],
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 6
    },
    "year": 2023
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1 (40\u2013500 mg QD)",
      "Phase 2 (100 or 300 mg QD)"
    ],
    "claims": [
      "3 of 3 patients with co-occurring AR H875/T878/L702H mutations achieved best PSA reductions >50%",
      "PSA50=42%",
      "3 of 5 patients with AR L702H achieved PSA50",
      "1 confirmed partial response",
      "1 unconfirmed partial response"
    ],
    "safety": [],
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 8
    },
    "year": 2023
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC",
      "CSPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1/2",
      "Phase 3"
    ],
    "claims": [
      "Promising efficacy signals and a good tolerability profile",
      "Precision medicine opportunity in a growing population with few treatment options",
      "Addresses an unmet need for durable and tolerable treatments in late-line settings"
    ],
    "safety": [],
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 9
    },
    "year": 2023
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 8
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "Disease-causing target protein"
    ],
    "modality": "PROTAC\u00ae",
    "e3_ligase": "E3 ubiquitin ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 9
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [
      "AR"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "potentially first- and best-in-class AR-targeted therapy",
      "Clear initial efficacy signal in dose escalation",
      "Safety profile acceptable for potential use in frontline settings",
      "80% Reduction",
      "Near complete regression of adenopathy",
      "Potential to address unmet patient need in 1L mCRPC and mCSPC (~45k patients)"
    ],
    "safety": [
      "acceptable for potential use in frontline settings"
    ],
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 12
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+ locally advanced or metastatic breast cancer",
      "2L+ ER+/HER2- mBC",
      "1L ER+ breast cancer"
    ],
    "therapeutic_areas": [
      "breast cancer"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Early evidence of ER degradation",
      "No DLTs; dose escalation continues",
      "Dose-proportional pharmacokinetics",
      "Superior ER degradation and tumor inhibition in preclinical studies",
      "Fast-to-market strategy"
    ],
    "safety": [
      "No DLTs"
    ],
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 13
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "AR",
      "ER"
    ],
    "modality": "PROTAC\u00ae degraders",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Degradation of AR and ER demonstrates proof-of-mechanism in human patients",
      "Safety initially observed in two different programs in two different patient populations",
      "ARV-110 overcame prior resistance to AR therapy, showing the translation of ARV-110\u2019s preclinical profile into patient benefit",
      "Reinforces our confidence in Arvinas\u2019 extensive and promising preclinical pipeline"
    ],
    "safety": [
      "initially observed in two different programs in two different patient populations"
    ],
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 14
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "oncology",
      "immuno-oncology",
      "neuroscience"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 15
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "BCL6",
      "KRAS",
      "Myc",
      "HPK1",
      "mHTT"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 17
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": "BCL6",
    "targets": [
      "BCL6"
    ],
    "modality": "PROTAC\u00ae",
    "e3_ligase": null,
    "indications": [
      "B-cell malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      ">95% degradation of BCL6 in vivo"
    ],
    "safety": [],
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 18
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "KRAS",
      "KRAS G12D",
      "KRAS G12V",
      "KRAS G12C"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "human cancer"
    ],
    "clinical_phases": [
      "in vivo"
    ],
    "claims": [
      "degraded >80% of KRAS G12C in vivo"
    ],
    "safety": [],
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 19
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": "PROTAC\u00ae degraders",
    "targets": [],
    "modality": "biotech",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "registrational studies"
    ],
    "claims": [
      "First PROTAC\u00ae degraders proven to benefit patients in registrational studies",
      "Sustainably nominating \u22651 clinical candidate per year",
      "Our PROTAC\u00ae Discovery Engine delivering candidates with tissue- and disease-specific degradation",
      "Completing build-out of the resources and capabilities to bring PROTAC\u00ae therapeutics to market"
    ],
    "safety": [],
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 22
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 23
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 3
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": "PROTAC protein degraders",
    "e3_ligase": "E3 Ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 4
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "recalcitrant targets where PROTAC technology shows differential biology",
      "targets requiring exquisite selectivity"
    ],
    "modality": null,
    "e3_ligase": [
      "database of E3 ligase attributes to guide library expansion"
    ],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "two clinical-stage programs with initial safety/PK data"
    ],
    "claims": [
      "95% success rate at degrading proteins of interest"
    ],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 5
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 7
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV\u2010110 inhibits tumor growth in an in vivo model of acquired enzalutamide resistance",
      "Daily and orally delivered ARV\u2010110 significantly inhibited tumor growth",
      "10 mpk ARV\u2010110: 70% tumor growth inhibition"
    ],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 9
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV\u2010110 demonstrates efficacy and plasma PSA reduction in an enzalutamide\u2010insensitive patient derived xenograft model",
      "Orally delivered ARV\u2010110 significantly inhibited tumor growth in these intrinsically enza\u2010insensitive tumors (TGI: 100%)",
      "Plasma PSA levels following ARV\u2010110 treatment significantly decreased vs. mice treated with vehicle or enzalutamide"
    ],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 10
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV\u2010110 pharmacokinetics are dose proportional",
      "exposure has reached the predicted efficacious range",
      "accumulation occurs between Day 1 and Day 15",
      "exposure at 140 mg entered the preclinical efficacious range associated with tumor growth inhibition"
    ],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 11
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Oral, daily dose of ARV\u2010471 inhibited tumor growth by 99% at 10 mpk and 106% at 30 mpk in an ESR1 mutant PDX model.",
      "Superior inhibitor of tumor growth compared to fulvestrant.",
      "In corresponding quantitative western blots, ER is reduced by 79% and 88% in the 10 mpk and 30 mpk arms, respectively, vs. 63% for fulvestrant."
    ],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 14
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "exposure reached the predicted efficacious range",
      "accumulation occurs between Day 1 and Day 15",
      "exposure at 30 mg entered the preclinical efficacious range associated with tumor growth inhibition"
    ],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 16
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": "Neurology Research Programs",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 18
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 20
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 25
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 26
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 27
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": "PROTAC protein degraders",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Eliminate pathogenic proteins",
      "Target scaffolding function",
      "Potential to treat 'undruggable' proteins",
      "Iterative mechanism of action",
      "Broad tissue penetration",
      "Orally bioavailable",
      "Ease of manufacturing"
    ],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 28
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "HER2",
      "BRAF"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "PROTAC degraders can disable target protein overexpression",
      "PROTAC created with lapatinib as the 'warhead' degrades natural and overexpressed HER2",
      "HER2 degraded despite increased RNA levels",
      "PROTAC degraders can differentiate between mutant and wild type proteins",
      "BRAF-targeted PROTAC degrades three mutants of BRAF (V600E, K601E, G466V) while sparing the wild type"
    ],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 29
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "p38\u03b1"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Weak or promiscuous ligands can be converted into potent and selective PROTAC degraders",
      "When developed into PROTAC degraders, weak binders can become potent degraders",
      "Foretinib is a relatively weak binder to p38\u03b1",
      "PROTAC 1 is a foretinib-based PROTAC degrader with a p38\u03b1 binding affinity of 11 \u03bcM",
      "Despite its 11 \u03bcM binding affinity, PROTAC 1 has a DC50 of 210 nM",
      "When developed into PROTAC degraders, promiscuous ligands can become selective degraders",
      "Foretinib binds to 133 protein kinases",
      "In cells treated with a foretinib-based PROTAC degrader, only a small subset of cellular proteins are degraded",
      "A PROTAC degrader based on foretinib has a nanomolar DC50 despite a 11 \u03bcM binding affinity"
    ],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 30
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "PROTAC\u00ae degraders can be engineered to cross the blood\u2010brain barrier (BBB)",
      "Micromolar rodent brain exposure achieved after peripheral (IV) administration",
      "Brain\u2010to\u2010plasma ratio >0.5 achievable with PROTAC degraders",
      "Over a 4\u2010hour time course, PROTAC degraders are more durable in the brain than in plasma"
    ],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 34
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 35
    },
    "year": 2020
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [
      "breast cancer"
    ],
    "clinical_phases": [],
    "claims": [
      "Potential to be the endocrine backbone of choice for ER+/HER2- breast cancer treatment",
      "Designed to be an oral, high-potency ER degrader with favorable safety profile"
    ],
    "safety": [
      "favorable safety profile"
    ],
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 4
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "estrogen receptor"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [
      {
        "date": "December 2020",
        "patients": 21,
        "clinical_benefit_rate": "42%",
        "evaluable_patients": 12,
        "clinical_benefit_patients": 5
      },
      {
        "date": "December 2021",
        "patients": 60,
        "clinical_benefit_rate": "40%",
        "evaluable_patients": 47,
        "clinical_benefit_patients": 19
      },
      {
        "description": "Continued robust signals of efficacy in a patient population expected to have highly ER-independent disease, due to 100% pretreatment with CDK4/6 inhibitors"
      },
      {
        "description": "Well-tolerated across all dose levels with no dose limiting toxicities up to 700mg"
      },
      {
        "description": "Majority (89%) of AEs reported were grade 1/2"
      },
      {
        "description": "ER degradation up to 89% continues to exceed reported degradation in fulvestrant and clinical-stage SERDs"
      }
    ],
    "safety": [
      {
        "description": "Well-tolerated across all dose levels with no dose limiting toxicities up to 700mg"
      },
      {
        "description": "Majority (89%) of AEs reported were grade 1/2"
      }
    ],
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 5
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "First-in-Human"
    ],
    "claims": [],
    "safety": [
      "Safety"
    ],
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 6
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- advanced breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "100% of patients in Phase 1 study were post- CDK4/6 inhibitor",
      "high rate of potential ER-independent resistance mechanisms",
      "Disease progression on CDK4/6 inhibitor",
      "After CDK4/6 inhibitor treatment, ~66% of breast cancers have ER-independent mechanisms of resistance",
      "\u2265 2 prior endocrine therapies in any setting",
      "Up to 3 prior chemotherapy regimens in advanced breast cancer",
      "Believed to be the only trial of an ER-targeting therapy requiring prior CDK4/6 treatment for all patients",
      "demonstrate poor outcomes following CDK4/6 inhibitor therapy, e.g., fulvestrant: Median PFS = 1.9 months, CBR = 13.7%"
    ],
    "safety": [],
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 7
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 8
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-471 demonstrates promising anti-tumor activity in late-line patients",
      "Antitumor activity in response-evaluable patients (n=38)*"
    ],
    "safety": [],
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 11
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": "oral, high-potency ER degrader",
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "robust signals of efficacy in a challenging patient population",
      "favorable safety profile",
      "clinical benefit rate (CBR) of 40%",
      "confirmed partial responses (PR)",
      "maximum ER degradation (mean, 64%)",
      "89% of TRAEs were grade 1/2 in severity with no DLTs"
    ],
    "safety": [],
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 13
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Superior degradation to published fulvestrant and SERD data",
      "Strong efficacy signal in a predominantly ER-independent population",
      "Well tolerated",
      "Potential for 1L/2L/3L approval as monotherapy or in combination",
      "Planned combinations with CDK inhibitors and other targeted therapies in adjuvant or early metastatic cancers"
    ],
    "safety": [
      "Well tolerated"
    ],
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 15
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 16
    },
    "year": null
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 1
    },
    "year": 2022
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 3
    },
    "year": 2022
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "100%",
      "79%*",
      "50%",
      "42%*",
      "34%\u2021",
      "32%",
      "30%",
      "19%",
      "10%*,\u2021",
      "11%\u2021",
      "100%",
      "0",
      "22%",
      "45%"
    ],
    "safety": [],
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 6
    },
    "year": 2022
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 7
    },
    "year": 2022
  },
  {
    "company": "arvinas",
    "program": "VERITAC",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "Potential Best-in-Class Profile"
    ],
    "safety": [],
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 17
    },
    "year": 2022
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 18
    },
    "year": 2022
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [
      "ARV-471 demonstrates strong CBR and mPFS in heavily treatment-resistant patients",
      "Favorable tolerability profile at 200 and 500 mg qd",
      "At 200 mg phase 3 dose, no dose reductions and one discontinuation",
      "ARV-471\u2019s tolerability is well suited for development across the disease continuum"
    ],
    "safety": [
      "ARV-471 is an investigational compound. Its safety and efficacy has not been established"
    ],
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 19
    },
    "year": 2022
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "ER"
    ],
    "modality": "PROTAC protein degrader",
    "e3_ligase": null,
    "indications": [
      "metastatic breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "potential to be a best-in-class ER-targeting therapy",
      "validated the evaluation of ARV-471 as a potential treatment for metastatic breast cancer",
      "continued efficacy signals and favorable tolerability profile support advancement to Phase 3 registrational studies"
    ],
    "safety": [
      "favorable tolerability profile"
    ],
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 20
    },
    "year": 2022
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 21
    },
    "year": 2022
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": "PROTAC",
    "e3_ligase": "E3 ligase",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Eliminate (rather than inhibit) disease-causing proteins",
      "Disrupt scaffolding functions of target proteins",
      "Bind and degrade classically 'undrugged' proteins",
      "Act iteratively (catalytically)",
      "Potential for oral delivery and achieve broad tissue distribution, including across the blood-brain-barrier"
    ],
    "safety": [],
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 3
    },
    "year": 2024
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 7
    },
    "year": 2024
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "familial Parkinson's Disease"
    ],
    "therapeutic_areas": [
      "neurodegeneration"
    ],
    "clinical_phases": [],
    "claims": [
      "LRRK2 PROTAC enhances lysosome-based degradation",
      "DQ-Red BSA can be used to monitor lysosome-mediated degradation",
      "LRRK2 PROTAC enhances lysosome degradation compared to the inhibitor",
      "Comparable pharmacology for target engagement observed for LRRK2 PROTAC and kinase inhibitors",
      "LRRK2 PROTAC induces enhanced lysosomal clearance"
    ],
    "safety": [],
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 9
    },
    "year": 2024
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "PSP",
      "AD"
    ],
    "therapeutic_areas": [
      "neurology"
    ],
    "clinical_phases": [],
    "claims": [
      "LRRK2 PROTAC degraders induce reduction of pathologic tau",
      "LRRK2 SNP implicated in progression accelerated time to death by 1 year in PSP",
      "LRRK2 PROTAC induces reduction of AD induced pathologic tau compared to inhibitor",
      "Reduction of pathologic (AT8) Tau induced by LRRK2 PROTAC",
      "Preliminary data indicate LRRK2 PROTAC induces pathologic tau protein reduction in two tauopathy mouse models (Tg4510 and PS19)"
    ],
    "safety": [],
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 10
    },
    "year": 2024
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      ">85% LRRK2 degradation in deep brain regions of cynomolgus monkeys after oral dosing",
      "87% decrease in Cortex",
      "87% decrease in Striatum",
      "89% decrease in Cerebellum"
    ],
    "safety": [],
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 11
    },
    "year": 2024
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2",
      "Tau",
      "\u03b1-syn",
      "mHTT"
    ],
    "modality": "PROTAC protein degraders",
    "e3_ligase": null,
    "indications": [
      "Parkinson\u2019s",
      "PSP",
      "Alzheimer\u2019s",
      "MSA",
      "Huntington\u2019s"
    ],
    "therapeutic_areas": [
      "neurodegenerative diseases"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Increase lysosome number and degradative capacity",
      "Reduce pathologic tau",
      "Degrade in deep brain regions following oral dosing",
      "Impact clinically relevant biomarkers in primates",
      "Potential to cross the blood brain barrier and degrade disease-causing proteins inside cells",
      "Specifically target pathogenic proteins in the brain",
      "Potential for oral therapies"
    ],
    "safety": [],
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 14
    },
    "year": 2024
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 15
    },
    "year": 2024
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 3
    },
    "year": 2026
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [
      "BTK"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "advanced CNS disease",
      "B-cell malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Removes both BTK enzymatic activity and scaffolding functions",
      "Degradation removes all functions of BTK unlike BTK inhibitors",
      "Acts catalytically with unprecedented potency",
      "Exquisitely selective degrader of BTK",
      "Active against wildtype BTK and overcomes BTK inhibitor resistance mutations",
      "Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 7
    },
    "year": 2026
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "advanced CNS disease",
      "B-cell malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "One molecule of bexobrutideg degrades thousands of BTK proteins per hour",
      "Degradation removes all functions of BTK unlike BTK inhibitors",
      "Acts catalytically with unprecedented potency",
      "Exquisitely selective degrader of BTK",
      "Active against wildtype BTK and overcomes BTK inhibitor resistance mutations",
      "Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 8
    },
    "year": 2026
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [
      "BTK"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "B-cell malignancies",
      "advanced CNS disease"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "The first 'deg' with a potential best-in-class profile",
      "Novel MOA against a clinically and commercially proven target",
      "Global proteomics analysis shows bexdeg selectively degrades BTK with no off-target degradation",
      "Degradation removes all functions of BTK unlike BTK inhibitors",
      "Acts catalytically with unprecedented potency",
      "Exquisitely selective degrader of BTK",
      "Active against wildtype BTK and overcomes BTK inhibitor resistance mutations",
      "Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 9
    },
    "year": 2026
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "B-cell malignancies",
      "advanced CNS disease"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "First 'deg' with a potential best-in-class profile",
      "Superior mutational coverage compared to BTK inhibitors",
      "Degradation removes all functions of BTK",
      "Acts catalytically with unprecedented potency",
      "Most potent cell killing",
      "Exquisitely selective degrader of BTK",
      "Active against wildtype BTK and overcomes BTK inhibitor resistance mutations",
      "Crosses the blood brain barrier with clinical responses",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 10
    },
    "year": 2026
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "CNS disease",
      "B-cell malignancies"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Only BTK degrader to demonstrate clinical activity in patients with CNS disease including complete responses",
      "Degradation removes all functions of BTK unlike BTK inhibitors",
      "Acts catalytically with unprecedented potency",
      "Exquisitely selective degrader of BTK",
      "Active against wildtype BTK and overcomes BTK inhibitor resistance mutations",
      "Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 11
    },
    "year": 2026
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [
      {
        "dose": "200 mg",
        "n": 19,
        "objective_response_rate": "73.7",
        "confidence_interval": "(48.8\u201390.9)"
      },
      {
        "dose": "600 mg",
        "n": 18,
        "objective_response_rate": "83.3",
        "confidence_interval": "(58.6\u201396.4)"
      }
    ],
    "safety": [],
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 16
    },
    "year": 2026
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "r/r CLL",
      "2L+ CLL",
      "WM",
      "NHL",
      "I&I"
    ],
    "therapeutic_areas": [
      "oncology",
      "inflammatory"
    ],
    "clinical_phases": [
      "Pivotal DAYBreak CLL-201 trial initiated in October 2025",
      "Confirmatory Phase 3 planned to start in 2026",
      "Phase 1b/2 combination study planned to start in 2026"
    ],
    "claims": [
      "Accelerated Approval",
      "2L+ CLL Confirmatory Monotherapy",
      "2L+ CLL Combination",
      "Potential 1L+ CLL Combination"
    ],
    "safety": [],
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 22
    },
    "year": 2026
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CLL",
      "r/r CLL",
      "I&I",
      "NHL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2",
      "Phase 3",
      "Phase 1",
      "Phase 1a/b"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 25
    },
    "year": 2026
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 26
    },
    "year": 2026
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic dermatitis",
      "Bullous pemphigoid",
      "Hidradenitis suppurativa",
      "Multiple sclerosis",
      "Chronic obstructive pulmonary disease",
      "Psoriatic Arthritis",
      "Crohn\u2019s disease",
      "Prurigo nodularis",
      "Chronic rhinosinusitis with nasal polyps",
      "Rheumatoid arthritis",
      "Chronic spontaneous urticaria",
      "Systemic lupus erythematosus without Lupus",
      "Cutaneous lupus erythematosus",
      "Eosinophilic esophagitis",
      "Warm autoimmune hemolytic anemia",
      "Ulcerative Colitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 27
    },
    "year": 2026
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "B-cell malignancies"
    ],
    "therapeutic_areas": [
      "CNS"
    ],
    "clinical_phases": [],
    "claims": [
      "Potent and exquisitely selective degrader of BTK",
      "Active against wildtype BTK and demonstrated ability to overcome treatment-emergent resistance mutations",
      "Addresses BTK scaffolding function unlike current BTK inhibitors",
      "Acts catalytically driving degradation at low free-plasma concentrations",
      "Crosses the blood brain barrier and demonstrated clinical activity in the CNS",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 6
    },
    "year": 2025
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CLL",
      "NHL"
    ],
    "therapeutic_areas": [
      "central nervous system"
    ],
    "clinical_phases": [],
    "claims": [
      "Potent and exquisitely selective degrader of BTK",
      "Active against wildtype BTK and demonstrated ability to overcome treatment-emergent resistance mutations",
      "Addresses BTK scaffolding function unlike current BTK inhibitors",
      "Acts catalytically driving degradation at low free-plasma concentrations",
      "Crosses the blood brain barrier and demonstrated clinical activity in the CNS",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 8
    },
    "year": 2025
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed/refractory CLL",
      "2L+ CLL",
      "1L+ CLL",
      "WM",
      "NHL"
    ],
    "therapeutic_areas": [
      "I&I",
      "Neuro",
      "derm",
      "heme"
    ],
    "clinical_phases": [
      "Phase 1/2",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "Accelerated Approval"
    ],
    "safety": [],
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 10
    },
    "year": 2025
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a"
    ],
    "claims": [
      {
        "Median PFS": "22.1 months",
        "n": 48,
        "95% CI": "11.2\u2013NE"
      },
      {
        "Median PFS follow-up": "16.6 months",
        "95% CI": "14.0\u201319.3"
      }
    ],
    "safety": [],
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 25
    },
    "year": 2025
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CLL",
      "NHL",
      "I&I"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b",
      "Phase 1a/b",
      "Phase 1 SAD/MAD",
      "Phase 1",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 45
    },
    "year": 2025
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 46
    },
    "year": 2025
  }
]